DOI: 10.1002/ejoc.201001020

Conjugate Addition of 2-Acetylindole Enolates to Unsaturated Oxazolopiperidone Lactams: Enantioselective Access to the Tetracyclic Ring System of Ervitsine

Mercedes Amat,*^[a] Begoña Checa,^[a] Núria Llor,^[a] Maria Pérez,^[a] and Joan Bosch^[a]

Dedicated to Prof. Carmen Nájera on the occasion of her 60th birthday

Keywords: Alkaloids / Nitrogen heterocycles / Lactams / Asymmetric synthesis / Cyclization / Michael addition

The stereochemical outcomes of the conjugate addition reactions of 2-acetylindole enolates to the unsaturated phenylglycinol-derived oxazolopiperidone lactams 1a-f have been studied. After reduction of the 2-acylindole carbonyl group, the Michael adduct cis-6 underwent a Lewis acid-promoted intramolecular α -amidoalkylation, leading enantioselectively to the tetracyclic ring system of the indole alkaloid ervitsine.

Introduction


Phenylglycinol-derived oxazolopiperidone lactams have proved to be versatile scaffolds that allow the regio- and stereocontrolled introduction of substituents at the different positions in the piperidine ring, thus providing access to enantiopure piperidines bearing virtually any type of substitution pattern and also to more complex piperidine-containing alkaloids, including indole alkaloids.^[11] In particular, the stereoselective introduction of carbon appendages at the piperidine 4-position through conjugate addition reactions requires the activation of this position, which can be accomplished by generation of a conjugated C=C bond, taking advantage of the lactam carbonyl group.

In previous work we have exploited conjugate additions of lower-order alkyl and aryl cyanocuprates to unsaturated oxazolopiperidone lactams for the enantioselective synthesis of *cis*-2,4-^[2] and *cis*-3,4-disubstituted piperidines,^[3] as well as 2,4-bridged^[2] and *cis*-3,4-fused piperidine^[4] derivatives, including the antidepressant drug (–)-paroxetine^[5] and synthetic intermediates en route to the indole alkaloid (–)-16-episilicine^[6] and alkaloids of the madangamine group.^[7]

Similarly, stereocontrolled conjugate addition reactions of sulfur-stabilized nucleophiles and indoleacetic acid ester enolates have been successfully employed as the key steps in enantioselective formal syntheses of uleine^[8] and *Strychnos* alkaloids.^[9,10]

Results and Discussion

Here we report conjugate additions of 2-acetylindole enolates to unsaturated phenylglycinol-derived oxazolopiperidone lactams and the subsequent construction of the tetracyclic framework of the indole alkaloid ervitsine through closure of the seven-membered ring by intramolecular α -amidoalkylation at the indole 3-position (Scheme 1).



Scheme 1. Synthetic strategy.

As the starting unsaturated lactams we selected the lactams 1a-f (Figure 1 and Scheme 2), each bearing an ethyl substituent at the 8-position of the oxazolopiperidone system. The preparation of the 3,8a-*cis* lactams $1a-d^{[3,6,8]}$ has





Figure 1. Unsaturated oxazolopiperidone lactams.

898

 [[]a] Laboratory of Organic Chemistry, Faculty of Pharmacy, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain Fax: +34-934-024-539 E-mail: amat@ub.edu

been reported previously. The new 3,8a-*trans* lactams 1e and 1f were prepared from the known lactams $2a^{[11]}$ and $2b^{[11]}$ via the respective seleno derivatives 3a and 3b, as outlined in Scheme 2.



Scheme 2. Preparation of the unsaturated lactams 1e and 1f.


Table 1 summarizes the results obtained from the conjugate addition reactions of the 2-acetylindole enolates **4a** and **4b** to the unsaturated lactams **1a–d**. The initial experiments were carried out with the enolate of 2-acetyl-1-methylindole (**4a**). When starting from the unsaturated lactam **1a**, which lacks the activating electron-withdrawing benzyloxycarbonyl group, the use of a slight excess (1.2 equiv.) of the nucleophile (Entry 1) led to the expected adducts **5** in low yield (24%) as a 1:2 epimeric mixture of C-7/C-8 *cis/trans* isomers. A similar result was observed with the enolate of 2-acetylindole (**4b**): compound **6** was obtained in 30% yield as a C-7/C-8 *cis/trans* epimeric mixture in a 1:3 ratio (Entry 2). The yields grew progressively higher as the excess of the nucleophile was increased (Entries 3 and 4), reaching 68% when 5 equiv. of enolate were used.

The relative configurations of the *cis* and *trans* isomers were evident from the shielding of the oxazolopiperidone C-6 signal in the ¹³C NMR spectrum of *cis*-6 ($\delta = 37.9$ ppm; compare with $\delta = 42.0$ ppm in *trans*-6) resulting from the axial ethyl substituent at C-8.

The facial selectivity of the conjugate addition reactions to lactam **1a** ($\mathbf{R}^1 = \mathbf{H}$) can be accounted for by considering that the addition of stabilized anions to α , β -unsaturated carbonyl compounds is a reversible process that in the case of 5-substituted 5,6-dihydro-2-pyridones leads to the thermodynamically more stable *trans*-4,5-disubstituted derivatives.^[12] Accordingly, in the reaction between the lactam **1a** and the acetylindole **4b** an increase in the proportion of the isomer *cis*-**6** was observed when the reaction was quenched after a short reaction time (Table 1, Entry 5).

In clear contrast from the stereochemical standpoint, similar conjugate addition reactions with the activated lactams **1b–d**, each bearing an additional activating alkoxycarbonyl substituent, led to the corresponding adducts **7–10** as diastereoisomeric mixtures in which the C-7/C-8 *cis* isomers predominated (Entries 6–10).^[13] As in the case of lactam **1a** above, the use of excess nucleophile (5 equiv.) in these reactions resulted in higher yields, lactams **9** and **10** being formed in 90% (compare Entries 8 and 9) and 87% yields (Entry 10), respectively, even after shorter reaction times.

The C-7/C-8 *cis* relative configuration in the major isomer *cis*-9 was confirmed by its conversion $[H_2, Pd(OH)_2;$ then toluene at reflux] into *cis*-6, the minor isomer obtained from lactam 1a (Scheme 3).



Scheme 3. Removal of the benzyloxycarbonyl substituent.

On the other hand, the predominance of the *cis* isomers in the conjugate additions to the lactams **1b**–**d** ($\mathbb{R}^1 = \mathbb{CO}_2\mathbb{R}$) can be explained by considering that in these cases the equilibration takes place to a lesser extent, as a consequence of the greater stabilities of the initially formed adducts (1,3dicarbonyl enolates). The process would then occur mainly under stereoelectronic control,^[14] which involves an axial approach of the nucleophile to the electrophilic C atom of the conjugate double bond from the *exo* face of the bicyclic

Table 1. Conjugate addition reactions of 2-acetylindoles to the unsaturated lactams 1a-d.

$\begin{array}{cccc} C_{6}H_{5} & & & & & & & \\ O & & & & & \\ R^{1} & & & & \\ R^{1} & & & \\ Ia-d \end{array} \qquad \begin{array}{cccc} Aa-b & R^{2} & & & \\ IDA, THF & & & & \\ R^{2} & O & cis \end{array} \qquad \begin{array}{ccccc} R^{1} & & & & \\ R^{1} & & & & \\ R^{2} & O & cis \end{array} \qquad \begin{array}{ccccc} C_{6}H_{5} & & & \\ R^{1} & & & & \\ R^{2} & O & cis \end{array} \qquad \begin{array}{cccccc} R^{1} & & & & \\ R^{1} & & & & \\ R^{2} & O & cis \end{array} \qquad \begin{array}{ccccccc} R^{1} & & & & \\ R^{2} & O & cis \end{array} \qquad \begin{array}{ccccccccccccccccccccccccccccccccccc$								
Entry	Lactam	Indole (equiv.)	Time	\mathbb{R}^1	R ²	Product	H ⁷ ,H ⁸ cis/trans ratio	Yield [%] ^[a]
1	1a	4a (1.2)	16 h	Н	Me	5	1:2	24
2	1a	4b (1.2)	10 h	Н	Н	6	1:3	30
3	1a	4b (2.5)	12 h	Н	Н	6	1:2.3	56
4	1a	4b (5.0)	24 h	Н	Н	6	1:2.3	68
5	1a	4b (5.0)	3 h	Н	Н	6	1:1.3	73
6	1b	4a (1.2)	23 h	CO_2Bn	Me	7	3:1	42
7	1c	4b (1.2)	16 h	CO_2Me	Н	8	3:1	38
8	1b	4b (1.2)	16 h	$\overline{CO_2Bn}$	Н	9	4:1	46
9	1b	4b (5.0)	5 h	CO_2Bn	Н	9	4:1	90
10	1d	4b (5.0)	4 h	$CO_2 tBu$	Н	10	5:1	87

[a] For the relative configuration of the epimerizable C-6 stereocentre, see Exp. section.

FULL PAPER

system as depicted in Figure 2. In fact, irreversible conjugate additions (of organocuprates, for instance) to unsaturated oxazolopiperidone lactams (**1a**–**f** or related lactams) have been reported to occur under stereoelectronic control with complete *exo* facial selectivity.^[15]





Figure 2. Stereoelectronic control in the conjugate additions.


Similar stereoelectronically controlled facial stereoselectivity was observed in the conjugate additions of the enolate of **4b** to the C-8 epimeric 3,8a-*trans* lactams **1e** and **1f** (Figure 2), with the corresponding *exo* adducts *cis*-**11** and *trans*-**12** being formed as the major isomers (Scheme 4).



Scheme 4. Conjugate addition reactions between 2-acetylindole and the unsaturated lactams **1e** and **1f**; ind = indolyl.

To study the closure of the seven-membered ring characteristic of ervitsine, we initially selected the lactam *trans*-6 (Scheme 5). However, all attempts to promote cyclization under a variety of acidic conditions (TiCl₄, CH₂Cl₂, reflux; BF₃·Et₂O, CH₂Cl₂, reflux; HCl, MeOH or C₆H₆) resulted in failure. The enamide **13**^[16] and its 8a-epimer **14** and the 8,8a-diastereoisomer **15** of *trans*-6 were the only isolable products.^[17] The stereochemistry of **14** and **15** was confirmed when these compounds were unambiguously prepared from *trans*-**12** and *cis*-**11**, respectively, by debenzylation [H₂, Pd(OH)₂] followed by decarboxylation.

Because the isolation of compounds 13-15 clearly indicated that the *N*-acyliminium cation^[18] had been formed,



Scheme 5.


the failure of the cyclization was attributed to the deactivating effect of the carbonyl group conjugated with the indole ring. For this reason, the acylindole *trans*-6 was converted into the alcohol 16 (Scheme 5) and then into the indolylethyl derivative 18 by hydrogenolysis of the corresponding acetate 17.

The desired cyclization at the indole 3-position, however, did not occur from **16** or **18** either, with only extensive decomposition being observed under a variety of acidic conditions.

Bearing in mind that the closure of the seven-membered ring of ervitsine and analogues has been successfully achieved by a related intramolecular iminium ion cyclization,^[19] we reasoned at this point that conformation factors could be responsible for the reluctance of the above C-7/C-8 *trans* derivatives to undergo intramolecular α -amidoalkylation: cyclization would involve an encumbered conformation in which both C-7 and C-8 substituents should be axial. To confirm this hypothesis, we decided to study related α -amidoalkylation reactions from C-7/C-8 *cis* lactams.

No cyclized products were detected, however, upon treatment of *cis*-6 with TiCl₄, the only isolable product being the 8a-epimer of *cis*-6.^[20] As in the above C-7/C-8 *trans* series, the 2-acylindole *cis*-6 was reduced to the alcohol **19** (Scheme 6) and then converted into the indolylethyl derivative **21** via the corresponding acetate **20**.

Although the alcohol **19** underwent extensive decomposition upon acidic treatment, to our delight, when the reduced derivative **21** was treated with TiCl₄ in CH₂Cl₂ at reflux, the tetracycle **22** was isolated in 58% yield.



Scheme 6. Access to the tetracyclic ring system of ervitsine.



In conclusion, conjugate addition reactions of 2-acetylindole enolates to phenylglycinol-derived unsaturated δ -lactams allow the stereocontrolled formation of C–C bonds at the piperidine 4-position. Depending on the absence or presence of an additional electron-withdrawing substituent conjugated with the C–C double bond, the reaction predominantly leads either to *trans*- or to *cis*-4,5-disubstituted enantiopure 2-piperidone derivatives, respectively.

The synthetic potential of the resulting Michael adducts has been demonstrated with the enantioselective construction of the tetracyclic ring system of ervitsine, a minor indole alkaloid isolated from *Pandaca boiteaui*^[21] that lacks the characteristic tryptamine moiety present in most monoterpenoid indole alkaloids. The strategy developed here, starting from an appropriate lactam bearing a C-8 substituent precursor of the exocyclic methylene group and involving a stereoselective conjugate addition and an intramolecular α -amidoalkylation as the key steps (see Scheme 1), may be applied to the enantioselective synthesis of ervitsine.^[22]

Experimental Section

General: Flash chromatography was carried out on SiO₂ (silica gel 60, SDS, 0.04–0.06 mm) or (when indicated) with a cartridge containing amine-functionalized silica. Optical rotations were measured with a Perkin–Elmer 241 polarimeter. High-resolution mass spectra (HMRS; LC/MSD TOF Agilent Technologies) were performed by the Serveis Científico-Tècnics, Barcelona. Microanalyses (Carlo–Erba 1106 analyzer) were performed by the Centre d'Investigació i Desenvolupament (CSIC), Barcelona. Only noteworthy IR absorptions (cm⁻¹; Perkin–Elmer 1600) are listed. NMR spectra were recorded at 200, 300, 400 or 500 MHz (¹H) and 75.4, 100.6 or 125.9 MHz (¹³C).

(3*R*,8*R*,8a*S*)-6-(Benzyloxycarbonyl)-8-ethyl-5-oxo-3-phenyl-6-(phenylselenyl)-2,3,6,7,8,8a-hexahydro-5*H*-oxazolo[3,2-*a*]pyridine (3a): Lithium bis(trimethylsilyl)amide (9.4 mL of a 1.0 M solution in THF, 9.4 mmol) was slowly added at -78 °C to a solution of lactam $2a^{[11]}$ (1.08 g, 4.24 mmol) in anhydrous THF (50 mL), and the resulting mixture was stirred for 90 min. Benzyl chloroformate (710 µL, 4.24 mmol) was then added, followed after 2 h of continuous stirring at -78 °C by a solution of C₆H₅SeCl (1.14 g, 5.09 mmol) in anhydrous THF (5 mL). The mixture was stirred for 2 h and poured into saturated aqueous NH₄Cl. The aqueous layer was extracted with EtOAc, and the combined organic extracts were dried and concentrated. Flash chromatography (hexane to hexane/ EtOAc 4:1) of the resulting oil afforded the corresponding selenides **3a** as a mixture of C-6 epimers (1.40 g, 62%).

Data for 3a: Orange oil. ¹H NMR (300 MHz, CDCl₃, 25 °C): $\delta = 0.74$ (t, J = 7.5 Hz, 3 H, CH₃ ethyl), 0.80 (t, J = 7.3 Hz, 3 H, CH₃ ethyl), 1.12–1.18 (m, 1 H, CH₂ ethyl), 1.12–1.22 (m, 1 H, CH₂ ethyl), 1.57–1.95 (m, 3 H, CH₂ ethyl, 7-H, 8-H), 1.61–1.72 (m, 2 H, CH₂ ethyl, 8-H), 1.83–2.00 (m, 2 H, 7-H), 2.33 (dd, J = 13.8, 2.1 Hz, 1 H, 7-H), 3.71 (dd, J = 9.0, 7.8 Hz, 1 H, 2-H), 3.78 (dd, J = 9.0, 7.5 Hz, 1 H, 2-H), 4.34 (d, J = 8.1 Hz, 1 H, 8a-H), 4.37 (dd, J = 9.0, 7.5 Hz, 1 H, 2-H), 4.46 (dd, J = 9.0, 7.8 Hz, 1 H, 2-H), 4.67 (d, J = 7.8 Hz, 1 H, 8a-H), 5.20 (d, J = 6.9 Hz, 1 H, CH₂C₆H₅), 5.20 (s, 2 H, CH₂C₆H₅), 5.24 (d, J = 6.9 Hz, 1 H, CH₂C₆H₅), 5.25 (d, J = 7.8 Hz, 1 H, 3-H), 5.30 (t, J = 7.5 Hz, 1

H, 3-H), 7.18–7.70 (m, 30 H, ArH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): δ = 10.5, 10.7 (CH₃ ethyl), 23.7, 24.0 (CH₂ ethyl), 32.5, 35.2 (C-7), 37.8, 39.3 (C-8), 54.2, 55.6 (C-6), 58.8 (C-3), 67.7, 67.8 (CH₂C₆H₅), 72.1, 72.3 (C-2), 92.0, 92.3 (C-8a), 125.7, 126.1 (C-*o*), 126.6, 126.7 (C-*m*), 127.3, 127.5 (C-*p*), 127.9, 128.0 (C-*o*), 128.0, 128.1 (C-*p*), 128.3, 128.4 (C-*m*), 128.5, 128.6 (C-*o*), 128.7, 128.8 (C-*m*), 129.3, 129.5 (C-*i*), 135.0, 135.1 (C-*i*), 138.0 (C-*p*), 138.5, 138.7 (C-*i*), 164.5, 164.9 (NCO), 169.9, 170.9 (COO) ppm.

(3*R*,8*S*,8*aS*)-6-(Benzyloxycarbonyl)-8-ethyl-5-oxo-3-phenyl-6-(phenylselenyl)-2,3,6,7,8,8a-hexahydro-5*H*-oxazolo[3,2-*a*]pyridine (3b): A mixture of C-6 epimeric selenides (3.46 g, 82%) was obtained as in the above preparation of 3a, from lactam $2b^{[11]}$ (2 g, 7.90 mmol) in THF (100 mL), LiHMDS (17.3 mL of a 1.0 M solution in THF), benzyl chloroformate (1.2 mL, 8.6 mmol) and C₆H₅SeCl (1.70 g, 8.80 mmol) in THF (20 mL). Pure isomers were isolated after subsequent flash chromatography (hexane to hexane/EtOAc 9:1).

Data for 3b (Higher R_f Epimer): Orange oil. $[a]_D^{22} = -84.0$ (c = 0.5, CHCl₃). ¹H NMR (300 MHz, CDCl₃, 25 °C): δ = 0.82 (t, J = 7.5 Hz, 3 H, CH₃ ethyl), 1.29–1.38 (m, 1 H, CH₂ ethyl), 1.53–1.63 (m, 1 H, CH₂ ethyl), 1.72–1.81 (m, 1 H, 8-H), 1.88–2.02 (m, 1 H, 7-H), 1.99 (dd, J = 12.9, 5.1 Hz, 1 H, 7-H), 3.73 (dd, J = 8.7, 6.9 Hz, 1 H, 2-H), 4.45 (t, J = 8.7 Hz, 1 H, 2-H), 4.60 (d, J =5.4 Hz, 1 H, 8a-H), 5.09 (d, J = 12.3 Hz, 1 H, $CH_2C_6H_5$), 5.32 (d, J = 12.3 Hz, 1 H, $CH_2C_6H_5$), 5.56 (t, J = 8.1 Hz, 1 H, 3-H), 7.13– 7.55 (m, 15 H, ArH) ppm. ¹³C NMR (75.4 MHz, CDCl₃, 25 °C): δ = 11.4 (CH₃ ethyl), 23.3 (CH₂ ethyl), 33.6 (C-7), 35.9 (C-8), 54.2 (C-6), 58.1 (C-3), 67.4 (CH₂C₆H₅), 70.8 (C-2), 87.8 (C-8a), 125.6 (C-o), 126.7 (C-m), 127.3 (C-p), 128.1 (C-o), 128.2 (C-m), 128.4 (Cp), 128.6 (C-o), 129.5 (C-m), 135.2 (C-p), 138.5 (C-i), 139.5 (C-i), 167.1 (NCO), 169.4 (COO) ppm. IR (film): $\tilde{v} = 1664$, 1724 cm⁻¹. C₂₉H₂₉NO₄Se (534.51): calcd. C 65.17, H 5.47, N 2.62; found C 65.19, H 5.58, N 2.54.

Data for 3b (Lower R_f Epimer): Orange oil. $[a]_{12}^{25} = -22.0$ (c = 0.5, CHCl₃). ¹H NMR (300 MHz, CDCl₃, 25 °C): $\delta = 0.81$ (t, J = 7.5 Hz, 3 H, CH₃ ethyl), 1.12–1.23 (m, 1 H, CH₂ ethyl), 1.55–1.67 (m, 1 H, CH₂ ethyl), 2.04 (dd, J = 15.0, 4.2 Hz, 1 H, 7-H), 2.22–2.28 (m, 1 H, 8-H), 2.56 (dd, J = 15.0, 6.6 Hz, 1 H, 7-H), 3.84 (dd, J = 8.7, 6.3 Hz, 1 H, 2-H), 4.34 (dd, J = 8.7, 7.5 Hz, 1 H, 2-H), 4.85 (d, J = 4.8 Hz, 1 H, 8a-H), 5.18 (s, 2 H, CH₂C₆H₃), 5.35 (t, J = 6.8 Hz, 1 H, 3-H), 7.06–7.47 (m, 15 H, ArH) ppm. ¹³C NMR (75.4 MHz, CDCl₃, 25 °C): $\delta = 11.6$ (CH₃ ethyl), 18.7 (CH₂ ethyl), 32.5 (C-7), 37.2 (C-8), 52.7 (C-6), 58.6 (C-3), 67.9 (CH₂C₆H₅), 71.6 (C-2), 89.0 (C-8a), 126.5 (C-o), 126.7 (C-m), 127.6 (C-p), 128.1 (C-o), 128.4 (CHAr), 128.7 (CHAr), 129.4 (CHAr), 135.2 (C-i), 137.7 (C-i), 139.2 (C-i), 165.1 (NCO), 170.2 (COO) ppm. IR (film): $\tilde{v} = 1661, 1732$ cm⁻¹. C₂₉H₂₉NO₄Se (534.51): calcd. C 65.17, H 5.47, N 2.62; found C 64.81, H 5.64, N 2.64.

(3*R*,8*R*,8a*S*)-6-(Benzyloxycarbonyl)-8-ethyl-5-oxo-3-phenyl-3,5,8,8atetrahydro-5*H*-oxazolo[3,2-*a*]pyridine (1e): A stream of ozone gas was bubbled through a cooled (-78 °C) solution of the selenides 3a (161 mg, 0.30 mmol) in anhydrous CH₂Cl₂ (50 mL) until the solution had turned pale blue (5 min). The solution was then purged with O₂, and the temperature was slowly raised to 25 °C. After 30 min of stirring, the mixture was poured intro brine and the aqueous layer was extracted with CH₂Cl₂. The combined organic extracts were dried and concentrated to give unsaturated lactam 1e, which because of its instability was used in the next reaction without further purification.

Data for 1e: Yellow oil. ¹H NMR (300 MHz, CDCl₃, 25 °C): δ = 1.10 (t, J = 7.5 Hz, 3 H, CH₃ ethyl), 1.57–1.66 (m, 1 H, CH₂ ethyl), 1.81–1.90 (m, 1 H, CH₂ ethyl), 2.53–2.61 (m, 1 H, 8-H), 3.94 (dd, J = 9.0, 6.0 Hz, 1 H, 2-H), 4.44 (dd, J = 9.0, 6.9 Hz, 1 H, 2-H),

FULL PAPER

5.10 (d, J = 9.3 Hz, 1 H, 8a-H), 5.26 (d, J = 5.3 Hz, 1 H, $CH_2C_6H_5$), 5.29 (m, 1 H, 3-H), 5.30 (d, J = 5.3 Hz, 1 H, $CH_2C_6H_5$), 7.19–7.40 (m, 11 H, 7-H, ArH) ppm.

(3*R*,8*S*,8*aS*)-6-(Benzyloxycarbonyl)-8-ethyl-5-oxo-3-phenyl-3,5,8,8atetrahydro-5*H*-oxazolo[3,2-*a*]pyridine (1f): The unsaturated lactam 1f (173 mg, 0.46 mmol) was obtained as in the above preparation of 1e, from a mixture of selenides 3b (246 mg, 0.46 mmol) in CH_2Cl_2 (15 mL). Because of its instability it was used in the next reaction without further purification.

Data for 1f: Orange oil. ¹H NMR (300 MHz, CDCl₃, 25 °C): δ = 0.99 (t, J = 7.5 Hz, 3 H, CH₃ ethyl), 1.38–1.48 (m, 1 H, CH₂ ethyl), 1.83–1.92 (m, 1 H, CH₂ ethyl), 2.76–2.81 (m, 1 H, 8-H), 4.00 (dd, J = 8.4, 5.7 Hz, 1 H, 2-H), 4.47 (dd, J = 8.4, 6.9 Hz, 1 H, 2-H), 5.22–5.26 (m, 3 H, CH₂C₆H₅, 3-H), 5.50 (d, J = 5.4 Hz, 1 H, 8a-H), 7.24–7.62 (m, 11 H, 7-H, ArH) ppm.

General Procedure for the Conjugate Addition Reactions: LDA was added to a cooled (-78 °C) solution of a 2-acetylindole (4a or 4b) in THF, and the mixture was stirred at this temperature for 1 h. A solution of an unsaturated lactam 1 in THF was then added to the solution (-78 °C). The resulting mixture was stirred at room temperature until the disappearance of the starting material was observed by TLC. The reaction was quenched by the addition of saturated aqueous NH₄Cl, and the mixture was extracted with EtOAc. The combined extracts were dried and concentrated to give a residue, which was purified by chromatography.

(3*R*,7*R*,8*S*,8a*R*)-8-Ethyl-7-[2-(1-methyl-2-indolyl)-2-oxoethyl]-5-oxo-3-phenyl-2,3,6,7,8,8a-hexahydro-5*H*-oxazolo[3,2-*a*]pyridine (*trans*-5) and Its 7*S* Epimer (*cis*-5): Compound 5 was obtained as a mixture of C-7 epimers as described in the General Procedure, from the lactam $1a^{[3b,8]}$ (200 mg, 0.82 mmol) in THF (30 mL), LDA (0.65 mL of a 1.5 M solution in cyclohexane, 0.98 mmol) and a solution of the indole 4a (170 mg, 0.98 mmol) in THF (30 mL) over 16 h. Flash chromatography (hexane/EtOAc from 1:1 to 3:7) afforded *trans*-5 (53 mg, 16%) and *cis*-5 (27 mg, 8%).

Data for *trans***-5**: Yellow foam. $[a]_{D}^{22} = 13.0$ (c = 0.5, CHCl₃). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 1.07 (t, *J* = 7.4 Hz, 3 H, CH₃ ethyl), 1.65–1.89 (m, 3 H, CH₂ ethyl, 8-H), 2.16 (dd, J = 18.2, 9.2 Hz, 1 H, 6-H), 2.50–2.60 (m, 2 H, 6-H, 7-H), 2.87 (dd, J = 16.2, 7.6 Hz, 1 H, CH₂CO), 3.10 (dd, J = 16.2, 5.2 Hz, 1 H, CH₂CO), 4.05 (s, 3 H, NCH₃), 4.09 (d, J = 9.0 Hz, 1 H, 2-H), 4.18 (dd, J = 9.0, 6.8 Hz, 1 H, 2-H), 4.73 (d, J = 7.6 Hz, 1 H, 8a-H), 4.96 (dd, J = 6.8, 1.2 Hz, 1 H, 3-H), 7.11 (s, 1 H, 3-H ind), 7.13-7.20 (m, 1 H, 7-H ind), 7.26–7.40 (m, 7 H, 5-H, 6-H ind, ArH), 7.67 (dd, J = 8.2, 1.2 Hz, 1 H, 4-H ind) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): $\delta = 10.2$ (CH₃ ethyl), 22.7 (CH₂ ethyl), 32.2 (C-7), 37.5 (C-6), 43.7 (CH₂CO), 44.8 (C-8), 58.4 (C-3), 73.9 (C-2), 91.1 (C-8a), 110.3 (C-3 ind), 111.8 (C-7 ind), 120.7 (C-4 ind), 122.9 (C-6 ind), 125.6 (C-5 ind), 126.2 (C-2 ind), 126.7 (C-o), 128.6 (C-m), 127.6 (C-p), 134.7 (C-i), 140.2 (C-3a ind), 141.2 (C-7a ind), 166.7 (NCO), 192.0 (CO) ppm. IR (film): $\tilde{v} = 1644$, 1661 cm⁻¹. HRMS: calcd. for $C_{26}H_{29}N_2O_3 [M + H]^+: 417.2178;$ found 417.2172.

Data for *cis***-5:** Yellow foam. ¹H NMR (200 MHz, CDCl₃, 25 °C): $\delta = 1.11$ (t, J = 7.4 Hz, 3 H, CH₃ ethyl), 1.38–1.63 (m, 1 H, CH₂ ethyl), 1.87–2.06 (m, 2 H, CH₂ ethyl, 8-H), 2.33–2.48 (m, 2 H, 6-H, 7-H), 2.94–3.03 (m, 3 H, 2×CH₂CO, 6-H), 4.06–4.22 (m, 2 H, 2-H), 4.08 (s, 3 H, NCH₃), 4.68 (d, J = 9.6 Hz, 1 H, 8a-H), 4.94 (d, J = 5.8 Hz, 1 H, 3-H), 7.12–7.43 (m, 9 H, ArH, ind-H), 7.69 (d, J = 8.0 Hz, 1 H, 4-H ind) ppm.

(3R,7R,8S,8aR)-8-Ethyl-7-[2-(2-indolyl)-2-oxoethyl]-5-oxo-3-phenyl-2,3,6,7,8,8a-hexahydro-5*H*-oxazolo[3,2-*a*]pyridine (*trans*-6) and Its 7*S* Epimer (*cis*-6): Compound 6 (Table 1, Entry 4) was obtained as a mixture of C-7 epimers as described in the General Procedure, from the unsaturated lactam $1a^{[3b,8]}$ (400 mg, 1.64 mmol) in THF (30 mL), LDA (11 mL of a 1.5 M solution in cyclohexane, 16.5 mmol) and a solution of 2-acetylindole (4b, 1.3 g, 8.2 mmol) in THF (50 mL) over 24 h. Flash chromatography (hexane/EtOAc 1:1 to 3:7) afforded *trans*-6 (316 mg, 48%) and *cis*-6 (132 mg, 20%).

The pure lactams *trans*-**6** (201 mg, 42%) and *cis*-**6** (150 mg, 31%) were also obtained after flash chromatography as above (Table 1, Entry 5), from the lactam **1a** (296 mg, 1.21 mmol) and acetylindole (**4b**, 970 mg, 6.12 mmol) after 3 h.

Data for *trans***-6:** Yellow foam. $[a]_{D}^{22} = -7.0$ (c = 0.5, CHCl₃). ¹H NMR (300 MHz, CDCl₃, 25 °C): δ = 1.04 (t, J = 7.2 Hz, 3 H, CH₃ ethyl), 1.64–1.88 (m, 3 H, CH₂ ethyl, 8-H), 2.16 (dd, J = 16.5, 7.6 Hz, 1 H, CH₂CO), 2.57 (m, 1 H, 7-H), 2.68 (dd, J = 16.5, 6.0 Hz, 1 H, 6-H), 2.79 (dd, J = 16.5, 9.2 Hz, 1 H, CH₂CO), 3.00 (dd, J = 16.5, 4.5 Hz, 1 H, 6-H), 4.10 (dd, J = 9.0, 1.2 Hz, 1 H, 2-H), 4.18 (dd, J = 9.0, 6.6 Hz, 1 H, 2-H), 4.71 (d, J = 8.1 Hz, 1 H, 3-H), 4.98 (d, J = 5.7 Hz, 1 H, 8a-H), 6.87 (d, J = 1.5 Hz, 1 H, 3-H ind), 7.04–7.08 (m, 1 H, 6-H ind), 7.18–7.25 (m, 1 H, 5-H ind), 7.28–7.41 (m, 7 H, ArH, 4-H ind), 10.05 (s, 1 H, NH) ppm. ¹³C NMR (75.4 MHz, CDCl₃, 25 °C): δ = 10.1 (CH₃ ethyl), 22.4 (CH₂) ethyl), 30.8 (C-7), 37.2 (CH₂CO), 42.0 (C-6), 44.6 (C-8), 58.3 (C-3), 73.8 (C-2), 90.7 (C-8a), 109.3 (C-3 ind), 112.5 (C-7 ind), 120.3 (C-4 ind), 122.6 (C-6 ind), 125.8 (C-5 ind), 126.7 (C-o), 127.0 (C-3a ind), 127.5 (C-m), 128.5 (C-p), 135.0 (C-7a ind), 137.7 (C-i), 141.3 (C-2 ind), 167.2 (NCO), 190.4 (CO) ppm. IR (film): $\tilde{v} = 1657$, 1735, 3312 cm⁻¹. C₂₅H₂₆N₂O₃·1/4 EtOAc (424.52): calcd. C 73.56, H 6.65, N 6.60; found C 73.77, H 6.63, N 6.47.

Data for *cis***-6:** Yellow foam. $[a]_{D}^{22} = -70.4$ (c = 0.5, CHCl₃). ¹H NMR (300 MHz, CDCl₃, 25 °C): δ = 1.10 (t, J = 7.3 Hz, 3 H, CH₃) ethyl), 1.45–1.54 (m, 1 H, CH₂ ethyl), 1.89–2.03 (m, 2 H, CH₂ ethyl, 8-H), 2.45 (m, 2 H, CH₂CO), 3.00 (m, 3 H, 2×6-H, 7-H), 4.04 (dd, J = 9.3, 4.3 Hz, 1 H, 2-H), 4.18 (dd, J = 9.3, 6.9 Hz, 1 H, 2-H), 4.68 (d, J = 9.3 Hz, 1 H, 3-H), 4.94 (d, J = 5.7 Hz, 1 H, 8a-H), 6.87 (d, J = 1.5 Hz, 1 H, 3-H ind), 7.11–7.36 (m, 9 H, ArH, H ind), 7.68 (dd, J = 8.1, 0.9 Hz, 1 H, 4-H ind), 9.50 (s, 1 H, NH) ppm. ¹³C NMR (75.4 MHz, CDCl₃, 25 °C): δ = 11.3 (CH₃) ethyl), 21.2 (CH₂ ethyl), 29.0 (C-7), 36.5 (CH₂CO), 37.9 (C-6), 43.6 (C-8), 59.4 (C-3), 73.8 (C-2), 90.2 (C-8a), 109.4 (C-3 ind), 112.4 (C-7 ind), 120.8 (C-4 ind), 122.8 (C-6 ind), 126.2 (C-5 ind), 126.3 (Co), 127.2 (C-3a ind), 127.4 (C-m), 128.4 (C-p), 135.0 (C-7a ind), 137.6 (C-i), 141.3 (C-2 ind), 166.8 (NCO), 190.7 (CO) ppm. IR (film): $\tilde{v} = 1657, 1735, 3325 \text{ cm}^{-1}$. $C_{25}H_{26}N_2O_3 \cdot 1/2H_2O$ (411.19): calcd. C 73.78, H 6.56, N 6.88; found C 73.40, H 6.27, N 6.98.

(3*R*,6*R*,7*R*,8*S*,8a*R*)-6-(Benzyloxycarbonyl)-8-ethyl-7-[2-(1-methyl-2indolyl)-2-oxoethyl]-5-oxo-3-phenyl-2,3,6,7,8,8a-hexahydro-5*H*oxazolo[3,2-*a*]pyridine (*cis*-7): Compound 7 was obtained as a mixture of diastereoisomers as described in the General Procedure, from the crude product obtained from the unsaturated lactam 1b^[3a] (500 mg, 1.32 mmol) in THF (10 mL), LDA (0.8 mL of a 2.0 M solution in THF/diethyl ether, 1.6 mmol) and a solution of the indole 4a (274 mg, 1.58 mmol) in THF (20 mL) over 23 h. Flash chromatography (hexane/EtOAc 9:1 to 1:1) afforded *cis*-7 (228 mg, 32%) and *trans*-7 (mixture of C-6 epimers; 76 mg, 10%).

Data for *cis*-7: Yellow foam. $[a]_{D}^{2D} = -69.8$ (c = 1.0, CHCl₃). ¹H NMR (300 MHz, CDCl₃, 25 °C): $\delta = 1.02$ (t, J = 7.5 Hz, 3 H, CH₃ ethyl), 1.40–1.50 (m, 1 H, CH₂ ethyl), 1.85–1.94 (m, 1 H, CH₂ ethyl), 2.42–2.51 (m, 1 H, 8-H), 2.95 (dd, J = 16.2, 11.1 Hz, 1 H, CH₂CO), 3.13 (dd, J = 16.2, 2.4 Hz, 1 H, CH₂CO), 3.15–3.19 (m, 1 H, 7-H), 3.45 (d, J = 0.3 Hz, 1 H, 6-H), 4.01–4.12 (m, 1 H, 2-H), 4.05 (s, 3 H, NCH₃), 4.18 (dd, J = 9.0, 6.9 Hz, 1 H, 2-H), 4.67 (d, J = 9.6 Hz, 1 H, 8a-H), 4.95 (t, J = 5.7 Hz, 1 H, 3-H), 5.06 (d,



J = 12.3 Hz, 1 H, $CH_2C_6H_5$), 5.13 (d, *J* = 12.3 Hz, 1 H, $CH_2C_6H_5$), 7.15–7.40 (m, 14 H, ArH, ind-H), 7.68 (dd, *J* = 7.8 Hz, 1 H, ind-H) ppm. ¹³C NMR (75.4 MHz, CDCl₃, 25 °C): δ = 11.1 (CH₃ ethyl), 20.8 (CH₂ ethyl), 32.2 (NCH₃), 33.1 (C-7), 37.4 (CH₂CO), 40.2 (C-8), 53.4 (C-6), 59.7 (C-3), 66.9 (CH₂C₆H₅), 74.0 (C-2), 90.3 (C-8a), 110.5 (C-3 ind), 114.4 (C-7 ind), 120.9 (C-5 ind), 122.9 (C-4 ind), 125.6 (CAr), 126.3 (CHAr), 126.4 (CHAr), 127.5 (CAr), 127.8 (CHAr), 128.0 (CAr), 128.4 (CHAr), 128.5 (CHAr), 134.5 (C-*i*), 135.6 (C-2 ind), 140.3 (C-3a ind), 140.6 (C-7a ind), 162.1 (NCO), 169.5 (COO), 190.8 (CO) ppm. IR (film): \tilde{v} = 1660, 1735 cm⁻¹. C₃₄H₃₄N₂O₅·1/3 EtOAc (579.73): calcd. C 73.18, H 6.37, N 4.83; found C 72.97, H 6.24, N 5.06.

(3*R*,6*S*,7*R*,8*S*,8a*R*)-8-Ethyl-7-[2-(2-indolyl)-2-oxoethyl]-6-(methoxycarbonyl)-5-oxo-3-phenyl-2,3,6,7,8,8a-hexahydro-5*H*-oxazolo-[3,2-*a*]pyridine (*cis*-8) and Its 6*R*,7*S* Diastereoisomer (*trans*-8): Compound 8 was obtained as a mixture of diastereoisomers as described in the General Procedure, from the crude product obtained from the unsaturated lactam $1c^{[3a]}$ (657 mg, 2.18 mmol) in THF (10 mL), LDA (3.84 mL of a 1.5 m solution in THF, 5.76 mmol) and a solution of 2-acetylindole (4b, 417 mg, 2.61 mmol) in THF (30 mL) over 16 h. Flash chromatography (hexane to hexane/ EtOAc 9:1) afforded *cis*-8 (290 mg, 29%) and *trans*-8 (90 mg, 9%).

Data for *cis***-8**: Yellow foam. $[a]_{D}^{22} = -65.3$ (c = 1.0, CHCl₃). ¹H NMR (300 MHz, CDCl₃, 25 °C): δ = 1.11 (t, J = 7.6 Hz, 3 H, CH₃ ethyl), 1.44–1.54 (m, 1 H, CH₂ ethyl), 1.89–1.99 (m, 1 H, CH₂ ethyl), 2.46–2.55 (m, 1 H, 8-H), 2.93 (dd, J = 16.2, 11.1 Hz, 1 H, CH₂CO), 3.12 (dd, J = 16.2, 2.7 Hz, 1 H, CH₂CO), 3.17–3.21 (m, 1 H, 7-H), 3.41 (d, J = 10.5 Hz, 1 H, 6-H), 3.60 (s, 3 H, OCH₃), 4.06 (dd, J = 9.0, 1.5 Hz, 1 H, 2-H), 4.20 (dd, J = 9.0, 7.2 Hz, 1 H, 2-H), 4.68 (d, J = 9.9 Hz, 1 H, 8a-H), 4.97 (dd, J = 7.2, 1.5 Hz, 1 H, 3-H), 7.13–7.40 (m, 9 H, ArH, ind-H), 7.68 (dd, J = 8.1, 0.9 Hz, 1 H, 4-H ind), 9.27 (s, 1 H, NH) ppm. ¹³C NMR (75.4 MHz, CDCl₃, 25 °C): δ = 11.2 (CH₃ ethyl), 20.0 (CH₂ ethyl), 33.4 (C-7), 35.8 (CH₂CO), 40.1 (C-8), 52.4 (C-6), 53.1 (OCH₃), 59.7 (C-3), 74.0 (C-2), 90.3 (C-8a), 109.6 (C-3 ind), 112.5 (C-7 ind), 121.0 (C-4 ind), 122.9 (C-5 ind), 126.5 (C-6 ind), 126.6 (C-0), 127.3 (C-2 ind), 127.5 (C-m), 128.3 (C-p), 134.8 (C-i), 137.7 (C-3a ind), 140.6 (C-7a ind), 162.4 (NCO), 170.2 (COO), 190.1 (CO) ppm. IR (film): $\tilde{v} = 1655$, 1736, 3324 cm⁻¹. C₂₇H₂₈N₂O₅·1/2 EtOAc (504.58): calcd. C 69.03, H 6.39, N 5.55; found C 68.99, H 6.16, N 5.59.

Data for *trans*-8: Yellow foam. $[a]_{D}^{22} = +3.6$ (c = 1.0, CHCl₃). ¹H NMR (300 MHz, CDCl₃, 25 °C): δ = 1.11 (t, J = 7.5 Hz, 3 H, CH₃ ethyl), 1.63-1.75 (m, 1 H, CH₂ ethyl), 1.75-1.87 (m, 1 H, CH₂ ethyl), 1.96-2.01 (m, 1 H, 8-H), 2.89-2.98 (m, 1 H, 7-H), 3.02-3.06 (m, 2 H, CH₂CO), 3.52 (d, J = 7.2 Hz, 1 H, 6-H), 3.69 (s, 3 H, OCH_3), 4.12 (dd, J = 9.3, 1.2 Hz, 1 H, 2-H), 4.21 (dd, J = 9.3, 6.6 Hz, 1 H, 2-H), 4.83 (d, J = 8.4 Hz, 1 H, 8a-H), 4.98–5.00 (m, 1 H, 3-H), 7.01 (d, J = 1.8 Hz, 1 H, 3-H ind), 7.11–7.45 (m, 8 H, ArH, ind-H), 7.66 (d, J = 8.1 Hz, 1 H, 4-H ind), 9.32 (s, 1 H, NH) ppm. ¹³C NMR (75.4 MHz, CDCl₃, 25 °C): δ = 10.3 (CH₃ ethyl), 23.1 (CH₂ ethyl), 33.7 (C-7), 41.1 (CH₂CO), 44.7 (C-8), 52.6 (OCH₃), 54.9 (C-6), 59.0 (C-3), 73.8 (C-2), 90.4 (C-8a), 109.6 (C-3 ind), 112.3 (C-7 ind), 120.9 (C-4 ind), 122.9 (C-5 ind), 126.8 (C-6 ind), 126.6 (C-o), 127.3 (C-2 ind), 127.5 (C-p), 128.5 (C-m), 134.8 (C-i), 137.6 (C-3a ind), 140.8 (C-7a ind), 162.7 (NCO), 170.0 (COO), 190.1 (CO) ppm. IR (film): $\tilde{v} = 1656$, 1737, 3310 cm⁻¹. C₂₇H₂₈N₂O₅·3/4H₂O (474.04): calcd. C 68.41, H 6.27, N 5.91; found C 68.12, H 6.10, N 5.64.

(3R,6R,7R,8S,8aR)-6-(Benzyloxycarbonyl)-8-ethyl-7-[2-(2-indolyl)-2-oxoethyl]-5-oxo-3-phenyl-2,3,6,7,8,8a-hexahydro-5*H*-oxazolo[3,2*a*]pyridine (*cis*-9) and Its 6S,7S Diastereoisomer (*trans*-9): Compound 9 was obtained as a mixture of diastereoisomers as described in the General Procedure, from the crude product obtained from the unsaturated lactam $1b^{[3a]}$ (1.55 g, 4.11 mmol) in THF (50 mL), LDA (27.4 mL of a 1.5 M solution in THF, 41.1 mmol) and a solution of 2-acetylindole (**4b**, 3.27 g, 20.5 mmol) in THF (100 mL) over 5 h. Flash chromatography (hexane to hexane/ EtOAc 1:1) afforded *cis*-**9** (accompanied by trace amounts of the C-6 epimer; 1.53 g, 69%) and *trans*-**9** (457 mg, 21%).

Data for *cis***-9**: Yellow foam. $[a]_{D}^{22} = -87.0$ (c = 0.2, CHCl₃). ¹H NMR (300 MHz, CDCl₃, 25 °C): δ = 1.02 (t, J = 7.6 Hz, 3 H, CH₃) ethyl), 1.40–1.50 (m, 1 H, CH₂ ethyl), 1.83–1.94 (m, 1 H, CH₂ ethyl), 2.42–2.51 (m, 1 H, 8-H), 2.92 (dd, J = 16.2, 11.1 Hz, 1 H, CH_2CO), 3.10 (dd, J = 16.2, 2.7 Hz, 1 H, CH_2CO), 3.16 (m, 1 H, 7-H), 3.47 (d, J = 1.2 Hz, 1 H, 6-H), 4.03 (dd, J = 9.0, 1.5 Hz, 1 H, 2-H), 4.19 (dd, J = 9.0, 7.2 Hz, 1 H, 2-H), 4.67 (d, J = 9.6 Hz, 1 H, 8a-H), 4.97 (dd, J = 7.2, 1.5 Hz, 1 H, 3-H), 5.03 (d, J =16.8 Hz, 1 H, $CH_2C_6H_5$), 5.08 (d, J = 16.8 Hz, 1 H, $CH_2C_6H_5$), 7.12–7.41 (m, 14 H, ArH), 7.69 (dd, J = 8.4, 1.2 Hz, 1 H, 4-H ind), 9.22 (s, 1 H, NH) ppm. ¹³C NMR (75.4 MHz, CDCl₃, 25 °C): δ = 11.1 (CH₃ ethyl), 20.7 (CH₂ ethyl), 33.4 (C-7), 35.8 (CH₂CO), 40.1 (C-8), 53.1 (C-6), 59.5 (C-3), 66.7 (CH₂C₆H₅), 73.8 (C-2), 90.0 (C-8a), 109.3 (C-3 ind), 112.6 (C-7 ind), 120.6 (C-2 ind), 122.5 (C-6 ind), 126.1 (C-5 ind), 126.2 (C-4 ind), 126.9, 127.2, 127.5, 127.7, 127.9, 128.1 (C-o, m, p), 134.6 (C-3a ind), 135.2 (C-7a ind), 140.5 (C-i), 137.7 (C-i), 162.2 (COO), 169.2 (NCO), 189.9 (CO) ppm. IR (film): $\tilde{v} = 1655$, 1735, 3320 cm⁻¹. C₃₃H₃₂N₂O₅·1/4 EtOAc (558.65): calcd. C 73.10, H 6.13, N 5.01; found C 73.08, H 6.00, N 4.99.

Data for *trans-9***:** Yellow foam. ¹H NMR (400 MHz, CDCl₃, 25 °C): $\delta = 0.99$ (t, J = 7.6 Hz, 3 H, CH₃ ethyl), 1.71–2.04 (m, 3 H, CH₂ ethyl, 8-H), 2.87–3.18 (m, 3 H, 2×CH₂CO, 7-H), 3.56 (d, J = 5.6 Hz, 1 H, 6-H), 4.01–4.20 (m, 2 H, 2-H), 4.71 (d, J = 8.4 Hz, 1 H, 8a-H), 4.97 (d, J = 6.0 Hz, 1 H, 3-H), 5.09 (d, J = 11.6 Hz, 1 H, CH₂C₆H₅), 5.14 (d, J = 11.6 Hz, 1 H, CH₂C₆H₅), 6.95 (d, J = 7.6 Hz, 1 H, 3-H ind), 7.12–7.41 (m, 13 H, ArH), 7.65 (d, J = 7.6 Hz, 1 H, 4-H ind), 9.09 (br. s, 1 H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): $\delta = 10.4$ (CH₃ ethyl), 23.1 (CH₂ ethyl), 34.9 (C-7), 41.1 (CH₂CO), 44.7 (C-8), 55.0 (C-6), 58.9 (C-3), 67.3 (CH₂C₆H₅), 73.8 (C-2), 90.4 (C-8a), 109.7 (C-3 ind), 112.3 (C-7 ind), 120.9 (C-2 ind), 123.0 (C-6 ind), 126.4 (C-5 ind), 126.5 (C-4 ind), 126.9–128.6 (C-*o*, *m*, *p*), 134.8 (C-3a ind), 137.5 (C-7a ind), 140.8 (C-*i*), 140.8 (C-*i*), 162.7 (COO), 169.9 (NCO), 190.0 (CO) ppm.

(3*R*,6*R*,7*R*,8*S*,8*aR*)-6-(*tert*-Butoxycarbonyl)-8-ethyl-7-[2-(2indolyl)-2-oxoethyl]-5-oxo-3-phenyl-2,3,6,7,8,8a-hexahydro-5*H*oxazolo[3,2-*a*]pyridine (*cis*-10): Compound 10 was obtained as a mixture of diastereoisomers as described in the General Procedure, from the crude unsaturated lactam 1d^[6] (1.0 g, 2.90 mmol) in THF (50 mL), LDA (19.5 mL of a 1.5 M solution in cyclohexane, 29 mmol) and a solution of 2-acetylindole (4b, 2.3 g, 14.5 mmol) in THF (100 mL) over 4 h. Flash chromatography (hexane to hexane/ EtOAc 1:1) afforded *cis*-10 (1.17 g, 80%) and *trans*-10 (mixture of C-6 epimers; 230 mg, 7%).

Data for *cis*-10: Yellow foam. $[a]_{22}^{22} = -21.5$ (c = 0.2, CHCl₃). ¹H NMR (400 MHz, CDCl₃, 25 °C): $\delta = 1.11$ (t, J = 7.6 Hz, 3 H, CH₃ ethyl), 1.34 [s, 9 H, (CH₃)₃C], 1.43–1.52 (m, 1 H, CH₂ ethyl), 1.88–1.96 (m, 1 H, CH₂ ethyl), 2.56 (ddd, J = 13.6, 9.2, 4.8 Hz, 1 H, 8-H), 2.91 (dd, J = 16.0, 10.8 Hz, 1 H, CH₂CO), 3.08 (dd, J = 16.0, 2.4 Hz, 1 H, CH₂CO), 3.20 (m, 1 H, 7-H), 3.30 (s, 1 H, 6-H), 4.04 (d, J = 8.4 Hz, 1 H, 2-H), 4.19 (dd, J = 8.4 Hz, 1 H, 2-H), 4.66 (d, J = 9.6 Hz, 1 H, 8a-H), 4.97 (d, J = 6.4 Hz, 1 H, 3-H), 7.12–7.40 (m, 9 H, ArH), 7.68 (d, J = 8.4 Hz, 1 H, 4-H ind), 9.36 (br. s, 1 H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): $\delta = 11.2$ (CH₃ ethyl), 20.8 (CH₂ ethyl), 27.8 [C(CH₃)₃], 32.9 (C-7), 36.0

 (CH_2CO) , 40.3 (C-8), 54.4 (C-6), 59.6 (C-3), 74.1 (C-2), 81.9 [$C(CH_3)_3$], 90.3 (C-8a), 109.5 (C-3 ind), 112.3 (C-7 ind), 121.0 (C-5 ind), 123.0 (C-6 ind), 126.5 (C-o), 126.6 (C-2 ind), 127.4 (C-m), 128.4 (C-p), 134.9 (C-3a ind), 137.5 (C-7a ind), 140.8 (C-i), 162.5 (NCO), 168.3 (COO), 190.1 (CO) ppm. IR (KBr): $\tilde{v} = 1662$, 1728, 2958 cm⁻¹. HRMS: calcd. for $C_{30}H_{35}N_2O_5$ [M + H]⁺: 503.2540; found 503.2541.

(3*R*,6*R*,7*S*,8*R*,8a*S*)-6-(Benzyloxycarbonyl)-8-ethyl-7-[2-(2-indolyl)-2-oxoethyl]-5-oxo-3-phenyl-2,3,6,7,8,8a-hexahydro-5*H*-oxazolo[3,2*a*]pyridine (*cis*-11): Compound 11 was obtained as a mixture of diastereoisomers as described in the General Procedure, from the crude unsaturated lactam 1e (161 mg, 0.43 mmol) in THF (10 mL), LDA (2.86 mL of a 1.5 M solution in THF, 4.3 mmol) and a solution of 2-acetylindole (4b, 342 mg, 2.15 mmol) in THF (15 mL) over 20 h. Flash chromatography (hexane/EtOAc 9:1 to EtOAc) afforded *cis*-11 (110 mg, 48%) and *trans*-11 (1:1 mixture of C-6 epimers; 32 mg, 14%).

Data for *cis***-11:** Yellow foam. $[a]_D^{22} = -101.1$ (c = 1.2, CHCl₃). ¹H NMR (300 MHz, CDCl₃, 25 °C): δ = 0.98 (t, J = 7.5 Hz, 3 H, CH₃) ethyl), 1.61 (m, 1 H, CH₂ ethyl), 1.76 (m, 1 H, CH₂ ethyl), 1.91 (m, 1 H, 8-H), 2.91 (m, 1 H, 7-H), 3.12 (dd, J = 5.4, 2.4 Hz, 2 H, CH₂CO), 3.67 (d, *J* = 9.3 Hz, 1 H, 6-H), 3.73 (dd, *J* = 9.0, 7.8 Hz, 1 H, 2-H), 4.49 (dd, J = 9.0, 7.8 Hz, 1 H, 2-H), 4.93 (d, J = 8.4 Hz, 1 H, 8a-H), 5.04 (d, J = 12.3 Hz, 1 H, $CH_2C_6H_5$), 5.13 (d, J =12.3 Hz, 1 H, $CH_2C_6H_5$), 5.29 (t, J = 7.8 Hz, 1 H, 3-H), 7.12–7.37 (m, 14 H, ArH, ind-H), 7.67 (d, J = 8.1 Hz, 1 H, 4-H ind), 9.21 (br. s, 1 H, NH) ppm. ¹³C NMR (75.4 MHz, CDCl₃, 25 °C): δ = 9.9 (CH₃ ethyl), 21.5 (CH₂ ethyl), 33.4 (C-7), 38.6 (CH₂CO), 40.3 (C-8), 55.4 (C-6), 58.7 (C-3), 67.4 (CH₂C₆H₅), 72.6 (C-2), 90.6 (C-8a), 109.4 (C-3 ind), 112.3 (CH ind), 121.0 (CH ind), 123.1 (CH ind), 125.7 (CHAr), 126.5 (CHAr), 127.4 (C-i), 127.6 (CHAr), 128.0 (CHAr), 128.2 (CHAr), 128.4 (CHAr), 128.8 (CHAr), 134.8 (C-i), 135.2 (C-2 ind), 137.4 (C-3a ind), 138.6 (C-7a), 164.1 (NCO), 170.1 (COO), 190.0 (CO) ppm. IR (KBr): $\tilde{v} = 1656$, 1735 cm⁻¹. C33H32N2O5 (536.62): calcd. C 73.86, H 6.01, N 5.22; found C 73.46, H 6.08, N 5.34.

[3*R*,6*R*/6*S*),7*S*,8*S*,8*aS*]-6-(Benzyloxycarbonyl)-8-ethyl-7-[2-(2indolyl)-2-oxoethyl]-5-oxo-3-phenyl-2,3,6,7,8,8a-hexahydro-5*H*oxazolo[3,2-*a*]pyridine (*trans*-12): Compound 12 was obtained as a mixture of diastereoisomers as described in the General Procedure, from the crude product obtained from the unsaturated lactam 1f (1 g, 2.65 mmol) in THF (50 mL), LDA (26.5 mL of a 1 M solution in THF, 26.5 mmol) and a solution of 2-acetylindole (4b, 2.11 g, 13.25 mmol) in THF (100 mL) over 5 h. Flash chromatography (hexane/EtOAc 9:1 to EtOAc) afforded *trans*-12 (9:1 mixture of C-6 epimers; 1.02 g, 72 %) and *cis*-12 (mixture of C-6 epimers; 211 mg, 14%).

Data for *trans*-12 (Major 6S Epimer): Yellow foam. ¹H NMR (400 MHz, CDCl₃, 25 °C): $\delta = 0.95$ (t, J = 7.2 Hz, 3 H, CH₃ ethyl), 1.26–1.41 (m, 1 H, CH₂ ethyl), 1.64–1.71 (m, 1 H, CH₂ ethyl), 2.23–2.31 (m, 1 H, 8-H), 2.98–3.04 (m, 1 H, 7-H), 3.09 (dd, J = 12.4, 6.0 Hz, 1 H, CH₂CO), 3.13 (dd, J = 12.4, 6.4 Hz, 1 H, CH₂CO), 3.66 (d, J = 8.8 Hz, 1 H, 6-H), 3.86 (dd, J = 8.8, 6.8 Hz, 1 H, 2-H), 4.45 (dd, J = 8.8, 8.0 Hz, 1 H, 2-H), 5.09 (d, J = 9.2 Hz, 1 H, 8a-H), 5.16 (d, J = 12.5 Hz, 1 H, $CH_2C_6H_5$), 5.19 (d, J = 12.5 Hz, 1 H, $CH_2C_6H_5$), 5.33 (t, J = 7.6 Hz, 1 H, 3-H), 7.10 (d, J = 1.4 Hz, 1 H, 3-H ind), 7.15–7.42 (m, 13 H, ArH, ind-H), 7.69 (t, J = 8.0 Hz, 1 H, ind-H), 9.09 (br. s, 1 H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): $\delta = 11.3$ (CH₃ ethyl), 19.9 (CH₂ ethyl), 33.1 (C-7), 40.5 (CH₂CO), 42.1 (C-8), 53.8 (C-6), 58.8 (C-3), 67.2 (CH₂C₆H₅), 72.3 (C-2), 88.0 (C-8a), 109.5 (C-3 ind), 112.2 (C-7 ind), 121.1 (C-4 ind), 123.2 (C-5 ind), 125.6 (C-6 ind), 126.3, 126.7, 127.8, 128.1

128.3, 128.4, 128.8, (C-*o*, C-*m*, C-*p*, C-3a ind), 134.7 (C-2 ind), 135.5 (C-7a ind), 139.1 (C-*i*), 166.0 (NCO), 169.6 (COO), 190.3 (CO) ppm. IR (film): $\tilde{v} = 1655$, 1736, 3324 cm⁻¹. HRMS: calcd. for C₃₃H₃₂N₂NaO₅ [M + Na]⁺: 559.2203; found 559.2207.

Data for trans-12 (Minor 6R Epimer): ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 1.00 (t, J = 7.4 Hz, 3 H, CH₃ ethyl), 1.30–1.42 (m, 2 H, CH₂ ethyl), 3.15-3.20 (m, 2 H, 7-H, 8-H), 3.25 (dd, J = 16.0, 7.2 Hz, 1 H, CH₂CO), 3.30 (dd, J = 16.0, 5.6 Hz, 1 H, CH₂CO), 3.74 (dd, J = 8.7, 7.6 Hz, 1 H, 2-H), 3.78 (d, J = 5.6 Hz, 1 H, 6-H), 4.52 (t, J = 8.4 Hz, 1 H, 2-H), 5.07 (d, J = 12.4 Hz, 1 H, $CH_2C_6H_5$, 5.13 (d, J = 12.4 Hz, 1 H, $CH_2C_6H_5$), 5.16 (masked, 1 H, 8a-H), 5.38 (t, J = 7.6 Hz, 1 H, 3-H), 7.00 (d, J = 1.4 Hz, 1 H, 3-H ind), 7.10–7.42 (m, 13 H, ArH, ind-H), 7.68 (t, J = 8.6 Hz, 1 H, ind-H), 9.07 (br. s, 1 H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): $\delta = 11.6$ (CH₃ ethyl), 19.5 (CH₂ ethyl), 32.0 (C-7), 38.4 (CH₂CO), 39.6 (C-8), 50.5 (C-6), 58.1 (C-3), 67.3 (CH₂C₆H₅), 71.9 (C-2), 87.6 (C-8a), 109.5 (C-3 ind), 112.2 (C-7 ind), 121.1 (C-4 ind), 123.2 (C-5 ind), 125.6 (C-6 ind), 126.6, 127.5, 128.4, 128.5, 128.6, 128.8, 128.9 (C-o, C-m, C-p, C-3a ind), 135.1 (C-2 ind), 134.8 (C-7a ind), 137.3 (C-i), 164.8, (NCO), 169.2 (COO), 190.1 ppm.

Conversion of *cis***-9 into** *cis***-6:** A solution of *cis***-9 (200 mg, 0.43 mmol) in EtOAc (10 mL) containing Pd(OH)₂ (20 mg) was hydrogenated with vigorous stirring at room temperature and atmospheric pressure for 24 h. The catalyst was removed by filtration, and the solvent was evaporated to give an oil, which was dissolved in toluene (30 mL). The resulting solution was heated at reflux for 16 h and concentrated to dryness. The residue was chromatographed (hexane/EtOAc 4:1 to EtOAc) to give** *cis***-6** (97 mg, 65%).

(3*R*,7*R*,8*S*,8a*S*)-8-Ethyl-7-[2-(2-indolyl)-2-oxoethyl]-5-oxo-3-phenyl-2,3,6,7,8,8a-hexahydro-5*H*-oxazolo[3,2-*a*]pyridine (14): Compound 14 (452 mg, 67%) was obtained as above, from *trans*-12 (900 mg, 1.68 mmol) and Pd(OH)₂ (30%, 270 mg) in EtOAc (50 mL), with subsequent heating at reflux in toluene (100 mL), after column chromatography (hexane to hexane/EtOAc 1:1).

Data for 14: Yellow foam. $[a]_{D}^{22} = -21.6$ (c = 0.5, CHCl₃). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 1.01 (t, J = 7.4 Hz, 3 H, CH₃ ethyl), 1.21-1.28 (m, 1 H, CH₂ ethyl), 1.71-1.79 (m, 1 H, CH₂ ethyl), 2.18 (ddd, J = 14.0, 6.0, 4.8 Hz, 1 H, 8-H), 2.36 (dd, J = 18.4, 3.2 Hz)1 H, CH₂CO), 2.63 (dd, J = 18.4, 6.4 Hz, 1 H, CH₂CO), 2.84 (m, 1 H, 7-H), 3.09–3.11 (m, 2 H, 6-H), 3.79 (dd, J = 8.8, 7.6 Hz, 1 H, 2-H), 4.48 (t, J = 8.8 Hz, 1 H, 2-H), 5.23 (d, J = 4.4 Hz, 1 H, 8a-H), 5.30 (t, J = 7.6 Hz, 1 H, 3-H), 7.14–7.41 (m, 9 H, ArH), 7.69 (d, J = 8.0 Hz, 1 H, 4-H ind), 9.35 (br. s, 1 H, NH) ppm. ¹³C NMR $(100.6 \text{ MHz}, \text{CDCl}_3, 25 \text{ °C}): \delta = 11.6 (\text{CH}_3 \text{ ethyl}), 18.7 (\text{CH}_2 \text{ ethyl}),$ 29.6 (C-7), 33.7 (CH₂CO), 40.7 (C-8), 41.9 (C-6), 58.3 (C-3), 72.2 (C-2), 88.0 (C-8a), 109.5 (C-3 ind), 112.3 (C-7 ind), 121.1 (C-5 ind), 123.1 (C-6 ind), 126.0 (C-o), 126.7 (C-2 ind), 127.7 (C-m), 128.9 (C-p), 134.9 (C-3a ind), 137.5 (C-7a ind), 139.6 (C-i), 168.1 (NCO), 190.7 (CO) ppm. IR (KBr): $\tilde{v} = 1649$, 3312 cm⁻¹. HRMS: calcd. for C₂₅H₂₇N₂O₃ [M + H]⁺: 403.2016; found 403.2014.

(3R,7R,8R,8aS)-8-Ethyl-7-[2-(2-indolyl)-2-oxoethyl]-5-oxo-3phenyl-2,3,6,7,8,8a-hexahydro-5*H*-oxazolo[3,2-*a*]pyridine (15): Compound 15 (288 mg, 62%) was obtained as above, from *cis*-11 (620 mg, 1.15 mmol) and Pd(OH)₂ (20%, 124 mg) in MeOH (40 mL), with subsequent heating at reflux in toluene (70 mL), after column chromatography (hexane to hexane/EtOAc 1:1).

Data for 15: Yellow foam. $[a]_D^{22} = -74.7$ (c = 0.67, CHCl₃). ¹H NMR (400 MHz, CDCl₃, 25 °C): $\delta = 1.08$ (t, J = 7.6 Hz, 3 H, CH₃ ethyl), 1.45–1.54 (m, 1 H, CH₂ ethyl), 1.75–1.90 (m, 2 H, CH₂ ethyl, 8-H), 2.54–2.66 (m, 2 H, 6-H, 7-H), 2.90 (m, 1 H, 6-H), 2.97 (d, J = 11.8 Hz, 1 H, CH₂CO), 3.08 (d, J = 11.8 Hz, 1 H, CH₂CO), 3.80



(t, J = 8.4 Hz, 1 H, 2-H), 4.56 (t, J = 8.4 Hz, 1 H, 2-H), 4.78 (d, J = 9.2 Hz, 1 H, 8a-H), 5.35 (t, J = 8.0 Hz, 1 H, 3-H), 7.12–7.41 (m, 9 H, ArH, H ind), 7.66 (d, J = 8.4 Hz, 1 H, ind-H), 9.26 (br. s, 1 H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): $\delta = 11.5$ (CH₃ ethyl), 22.1 (CH₂ ethyl), 29.0 (C-7), 36.1 (*C*H₂CO), 37.4 (C-6), 44.0 (C-8), 58.3 (C-3), 72.4 (C-2), 90.9 (C-8a), 109.4 (C-3 ind), 112.3 (C-7 ind), 121.1 (C-4 ind), 123.0 (C-5 ind), 125.9 (C-o), 126.7 (C-6 ind), 127.4 (C-2 ind), 127.8 (C-m), 129.0 (C-p), 135.0 (C-i), 137.5 (C-3a), 139.7 (C-7a), 168.3 (NCO), 190.9 (CO) ppm. IR (KBr): $\tilde{v} = 1648$ cm⁻¹. HRMS: calcd. for C₂₅H₂₇N₂O₃ [M + H]⁺: 403.2016; found 403.2018. C₂₅H₂₆N₂O₃·1/2H₂O (411.50): calcd. C 72.97, H 6.61, N 6.81; found C 72.94, H 6.61, N 6.45.

(3*R*,7*R*,8*S*,8a*R*)-8-Ethyl-7-[2-hydroxy-2-(2-indolyl)ethyl]-5-oxo-3phenyl-2,3,6,7,8,8a-hexahydro-5*H*-oxazolo[3,2-*a*]pyridine (16): NaBH₄ (117 mg, 3.11 mmol) was slowly added at 0 °C to a solution of *trans*-6 (128 mg, 0.31 mmol) in MeOH (11 mL). The mixture was stirred at 0 °C for 1 h and the temperature was slowly raised to 25 °C. The mixture was concentrated, water was added, and the aqueous layer was extracted with Et₂O. The combined organic extracts were dried and concentrated to give a foam, which was chromatographed (hexane/EtOAc 1:1 to EtOAc) to afford the alcohol 16 as a mixture of epimers (115 mg, 90%).

Data for 16 (Higher R_f Epimer): Yellow foam. ¹H NMR (400 MHz, CDCl₃, 25 °C): $\delta = 0.80$ (t, J = 7.4 Hz, 3 H, CH₃ ethyl), 1.37–1.62 (m, 5 H, CH₂ ethyl, CH₂CHOH, 7-H, 8-H), 1.88 (dd, J = 16.8, 7.2 Hz, 1 H, 6-H), 1.97 (dd, J = 10.4, 8.0 Hz, 1 H, CH₂CHOH), 2.22 (br. s, 1 H, OH), 2.43 (dd, J = 16.8, 4.4 Hz, 1 H, 6-H), 3.92 (dd, J = 8.8, 1.6 Hz, 1 H, 2-H), 3.96 (dd, J = 8.8, 6.0 Hz, 1 H, 2-H), 4.20 (d, J = 7.6 Hz, 1 H, 8a-H), 4.59 (m, 1 H, CHOH), 4.77 (d, J = 5.2 Hz, 1 H, 3-H), 6.20 (s, 1 H, 3-H ind), 7.02–7.27 (m, 8 H, ArH, ind-H), 7.50 (d, J = 7.2 Hz, 1 H, 4-H ind), 9.16 (br. s, 1 H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): $\delta = 9.5$ (CH₃ ethyl), 21.2 (CH₂ ethyl), 31.2 (C-7), 37.4 (C-6), 40.5 (CH₂CHOH), 44.4 (C-8), 58.7 (C-3), 66.6 (CHOH), 73.7 (C-2), 90.5 (C-8a), 98.9 (C-3 ind), 111.3 (C-7 ind), 119.6 (C-5 ind), 120.3 (C-4 ind), 121.7 (C-6 ind), 126.5 (C-o), 127.6 (C-p), 128.0 (C-2 ind), 128.5 (C-m), 136.0 (C-3a ind), 140.8 (C-7a ind), 141.2 (C-i), 167.6 (NCO) ppm.

Data for 16 (Lower R_f Epimer): Yellow foam. ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 0.91 (t, J = 7.3 Hz, 3 H, CH₃ ethyl), 1.19–1.26 (m, 1 H, CH₂CHOH), 1.41–1.45 (m, 1 H, 8-H), 1.49–1.59 (m, 1 H, CH₂ ethyl), 1.68 (ddd, J = 14.4, 7.2, 4.0 Hz, 1 H, CH₂ ethyl), 1.88-1.92 (m, 1 H, 6-H), 1.95–2.04 (m, 2 H, CH₂CHOH, 7-H), 2.21 (br. s, 1 H, OH), 2.55 (dd, J = 16.4, 4.8 Hz, 1 H, 6-H), 3.91–3.97 (m, 2 H, 2-H), 4.29 (d, J = 9.2 Hz, 1 H, 8a-H), 4.73 (d, J = 9.2 Hz, 1 H, CHOH), 4.78 (d, J = 4.8 Hz, 1 H, 3-H), 6.18 (s, 1 H, 3-H ind), 7.04 (dd, J = 6.4, 1.2 Hz, 1 H, 7-H ind), 7.08 (dd, J = 7.6, 1.6 Hz, 1 H, 5-H ind), 7.09–7.24 (m, 6 H, ArH, 6-H ind), 7.53 (d, J = 8.0 Hz, 1 H, 4-H ind), 9.24 (br. s, 1 H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): δ = 9.3 (CH₃ ethyl), 20.5 (CH₂ ethyl), 29.2 (C-7), 36.5 (C-6), 39.7 (CH₂CHOH), 44.2 (C-8), 59.0 (C-3), 64.4 (CHOH), 73.7 (C-2), 90.6 (C-8a), 97.5 (C-3 ind), 111.1 (C-7 ind), 119.4 (C-5 ind), 120.2 (C-4 ind), 121.3 (C-6 ind), 126.4 (C-o), 127.6 (C-p), 128.2 (C-2 ind), 128.6 (C-m), 135.8 (C-3a ind), 141.2 (C-7a ind), 142.4 (C-i), 167.7 (NCO) ppm.

(3*R*,7*R*,8*S*,8a*R*)-7-[2-Acetyl-2-(2-indolyl)ethyl]-8-ethyl-5-oxo-3phenyl-2,3,6,7,8,8a-hexahydro-5*H*-oxazolo[3,2-*a*]pyridine (17): DMAP (8 mg, 0.06 mmol) and Ac₂O (140 μ L, 1.48 mmol) were added to a cooled (0 °C) solution of the alcohols 16 (135 mg, 0.34 mmol) in CH₂Cl₂ and pyridine (2 mL, 4:1). The mixture was stirred at room temp. for 4 h, diluted with CHCl₃ and successively washed with aqueous HCl (1 N) and saturated aqueous NaHCO₃. The organic solution was dried and concentrated to afford an epimeric mixture of acetates **17** (86 mg, 57%), which was used in the next reaction without further purification.

Data for 17: Yellow foam. ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 0.87 (t, J = 7.2 Hz, 3 H, CH₃ ethyl), 1.04 (t, J = 7.4 Hz, 3 H, CH₃ ethyl), 1.12–1.17 (m, 2 H, 7-H), 1.23–2.21 (m, 8 H, CH₂ ethyl, CH2CHO, 8-H), 2.20 (s, 3 H, CH3CO), 2.25 (s, 3 H, CH3CO), 2.55-2.63 (m, 2 H, CH_2CHO), 2.34 (dd, J = 14.0, 6.8 Hz, 1 H, 6-H), 3.32–3.49 (m, 3 H, 6-H), 4.01 (d, J = 9.0 Hz, 1 H, 2-H), 4.05 (d, J = 8.8 Hz, 1 H, 2-H), 4.07 (d, J = 8.8 Hz, 1 H, 2-H), 4.17 (dd, J = 9.0, 6.8 Hz, 1 H, 2-H), 4.47-4.54 (m, 3 H, CH₂CHO, 8a-H), 4.70 (d, J = 8.4 Hz, 1 H, 8a-H), 4.90 (d, J = 6.4 Hz, 1 H, 3-H), 4.95 (d, J = 6.0 Hz, 1 H, 3-H), 6.33 (s, 1 H, 3-H ind), 6.44 (s, 1 H, 3-H ind), 7.10 (dd, J = 14.8, 7.2 Hz, 1 H, ind-H), 7.17 (dd, J = 14.8, 7.2 Hz, 1 H, ind-H), 7.07-7.59 (m, 18 H, ArH, ind-H), 8.30 (br. s, 1 H, NH) ppm. $^{13}\mathrm{C}$ NMR (100.6 MHz, CDCl₃, 25 °C): δ = 9.6, 9.9 (CH₃ ethyl), 15.2, 15.3 (CH₂ ethyl), 21.5, 21.6 (COCH₃), 30.3, 30.9 (C-7), 36.9, 37.4 (C-6), 44.8, 44.9 (CH₂CO), 58.7, 58.7 (C-3), 64.3, 64.5 (CHOAc), 73.9, 74.0 (C-2), 90.7, 91.1 (C-8a), 100.4, 102.1 (C-3 ind), 110.9, 111.0 (C-7 ind), 119.8, 119.9 (C-5 ind), 120.4, 120.5 (C-4 ind), 121.8, 122.1 (C-6 ind), 126.4, 126.5 (C-o), 127.5 (C-p), 128.0, 128.2 (C-2 ind), 128.6 (C-m), 135.9, 136.2 (C-3a ind), 137.7, 139.4 (C-3a ind), 141.2, 141.3 (C-i), 166.6 (NCO), 166.8 (COO) ppm.

(3*R*,7*R*,8*S*,8a*R*)-8-Ethyl-7-[(2-indolyl)ethyl]-5-oxo-3-phenyl-2,3,6,7,8,8a-hexahydro-5*H*-oxazolo[3,2-*a*]pyridine (18): A solution of acetates 17 (160 mg, 0.36 mmol) in EtOAc (25 mL) containing Pd-C (20%, 17 mg) was hydrogenated at room temp. for 4 d at atmospheric pressure. The catalyst was removed by filtration, and the solvent was evaporated to give an oil. Flash chromatography (hexane/EtOAc 9:1 to 4:1) afforded 18 (70 mg, 50%).

Data for 18: Yellow foam. ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 0.99 (t, J = 7.6 Hz, 3 H, CH₃ ethyl), 1.63–2.18 (m, 7 H, CH₂ ethyl, 7-H, 8-H, indCH₂CH₂, indCH₂CH₂), 2.49–2.64 (m, 1 H, indCH₂CH₂), 2.53 (dd, J = 15.0, 6.0 Hz, 1 H, 6-H), 2.77 (ddd, J = 15.0, 9.6, 4.8 Hz, 1 H, 6-H), 4.06 (dd, J = 9.2, 1.2 Hz, 1 H, 2-H), 4.16 (dd, J = 9.2, 6.8 Hz, 1 H, 2-H), 4.63 (d, J = 8.4 Hz, 1 H, 8a-H), 4.94 (d, J = 5.6 Hz, 1 H, 3-H), 6.20 (s, 1 H, 3-H ind), 7.03–7.57 (m, 9 H, ArH, ind-H), 8.22 (br. s, 1 H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): δ = 10.0 (CH₃ ethyl), 22.0 (CH₂ ethyl), 24.9 (C-6), 33.2 (C-7, indCH₂CH₂), 36.8 (indCH₂), 45.1 (C-8), 58.7 (C-3 ind), 119.7 (C-4 ind), 121.0 (C-6 ind), 126.4, 126.6 (C-o), 127.6 (C-p), 128.6 (C-m), 128.7 (C-2 ind), 135.9 (C-3a ind), 138.6 (C-7a ind), 141.2 (C-i), 167.0 (NCO) ppm.

(3*R*,7*S*,8*S*,8*aR*)-8-Ethyl-7-[2-hydroxy-2-(2-indolyl)ethyl]-5-oxo-3phenyl-2,3,6,7,8,8a-hexahydro-5*H*-oxazolo[3,2-*a*]pyridine (19): As in the above reduction of *trans*-6, a foam was obtained from a solution of *cis*-6 (1.05 mg, 2.60 mmol) in THF (50 mL) and NaBH₄ (148 mg, 3.91 mmol) for 3 h. Flash chromatography (hexane/ EtOAc 1:1 to EtOAc) gave two epimeric alcohols 19 (higher $R_{\rm f}$ epimer: 462 mg, 44%; lower $R_{\rm f}$ epimer: 308 mg, 29%).

Data for 19 (Higher R_f Epimer): Yellow foam. ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 1.03 (t, J = 7.4 Hz, 3 H, CH₃ ethyl), 1.38–2.49 (m, 8 H, CH₂ ethyl), CH₂CHOH, 6-H, 7-H, 8-H), 3.14 (br. s, 1 H, OH), 3.94–4.04 (m, 2 H, 2-H), 4.50 (d, J = 8.4 Hz, 1 H, 8a-H), 4.81 (m, 2 H, CHOH, 3-H), 6.29 (s, 1 H, 3-H ind), 7.07 (t, J = 7.4 Hz, 1 H, ind-H), 7.13 (t, J = 7.4 Hz, 1 H, ind-H), 7.21–7.31 (m, 6 H, ArH, ind-H), 7.54 (d, J = 7.6 Hz, 1 H, 4-H ind), 8.78 (br. s, 1 H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): δ = 11.2 (CH₃ ethyl), 20.7 (CH₂ ethyl), 28.6 (C-7), 35.4 (C-6), 36.9 (CH₂CHOH), 43.8 (C-8), 59.3 (CHOH), 65.3 (C-3), 73.8 (C-2), 90.3 (C-8a), 98.1 (C-3 ind), 111.0 (C-7 ind), 119.7 (C-5 ind), 120.4

FULL PAPER

(C-4 ind), 121.7 (C-6 ind), 126.3 (C-*o*), 127.6 (C-*p*), 128.2 (C-2 ind), 128.6 (C-*m*), 135.7 (C-3a ind), 141.4 (C-7a ind), 141.6 (C-*i*), 167.7 (NCO) ppm.

Data for 19 (Lower *R*_f **Epimer):** Yellow foam. ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 0.83 (t, *J* = 7.4 Hz, 3 H, CH₃ ethyl), 1.34–2.72 (m, 8 H, CH₂ ethyl), *CH*₂CHOH, 6-H, 7-H, 8-H), 3.87–4.00 (m, 2 H, 2-H), 4.51 (d, *J* = 6.8 Hz, 1 H, 8a-H), 4.62–4.78 (m, 2 H, CHOH, 3-H), 6.27 (s, 1 H, 3-H ind), 7.66–7.28 (m, 8 H, ArH, ind-H), 7.54 (d, *J* = 7.6 Hz, 1 H, 4-H ind), 9.20 (br. s, 1 H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): δ = 11.2 (CH₃ ethyl), 20.8 (CH₂ ethyl), 29.7 (C-7), 30.8 (C-6), 38.0 (*C*H₂CHOH), 44.2 (C-8), 59.3 (*C*HOH), 68.2 (C-3), 73.8 (C-2), 90.3 (C-8a), 99.2 (C-3 ind), 111.3 (C-7 ind), 119.6 (C-5 ind), 120.3 (C-4 ind), 121.8 (C-6 ind), 126.3 (C-*o*), 127.6 (C-*p*), 127.9 (C-2 ind), 128.6 (C-*m*), 136.2 (C-3a ind), 141.0 (C-7a ind), 141.4 (C-*i*), 170.2 (NCO) ppm.

(3*R*,7*S*,8*S*,8*aR*)-7-[2-Acetyl-2-(2-indolyl)ethyl]-8-ethyl-5-oxo-3phenyl-2,3,6,7,8,8a-hexahydro-5*H*-oxazolo[3,2-*a*]pyridine (20): The two epimeric acetates 20 (higher R_f epimer: 440 mg, 52%; lower R_f epimer: 300 mg, 35%) were obtained as in the above preparation of 17 (reaction time 14 h), from the alcohols 19 (770 mg, 1.90 mmol), DMAP (8 mg, 0.06 mmol) and Ac₂O (0.8 mL, 7.61 mmol) in CH₂Cl₂ and pyridine (12.5 mL, 4:1), after column chromatography (hexane to hexane/EtOAc 9:1).

Data for 20 (Higher R_f Epimer): Yellow foam. $[a]_D^{22} = +47.5$ (c = 1.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 1.11 (t, J = 7.3 Hz, 3 H, CH₃ ethyl), 1.54–1.63 (m, 1 H, CH₂ ethyl), 1.79 (dd, J = 11.2, 2.8 Hz, 1 H, 6-H), 1.92–1.99 (m, 2 H, CH₂ ethyl, 8-H), 2.10 (s, 3 H, CH₃CO), 2.26–2.31 (m, 1 H, 7-H), 2.35–2.45 (m, 3 H, CH₂CHO, 6-H), 2.54 (d, J = 17.6 Hz, 1 H, CH₂CHO), 3.99 (dd, J = 9.2, 1.2 Hz, 1 H, 2-H), 4.12 (dd, J = 9.2, 6.8 Hz, 1 H, 2-H), 4.62 (d, J = 9.2 Hz, 1 H, 8a-H), 4.89 (d, J = 6.8 Hz, 1 H, 3-H), 6.03(dd, J = 10.8, 2.4 Hz, 1 H, CH₂CHO), 6.49 (d, J = 2.4 Hz, 1 H, 3-H ind), 7.08-7.32 (m, 8 H, ArH, ind-H), 7.58 (d, J = 7.2 Hz, 1 H, ind-H), 9.18 (br. s, 1 H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): $\delta = 11.0$ (CH₃ ethyl), 20.6 (CH₂ ethyl), 21.1 (OCH₃), 28.9 (C-7), 32.3 (C-6), 37.1 (CH₂CHO), 43.7 (C-8), 59.4 (C-3), 67.5 (CH₂CHO), 73.9 (C-2), 90.1 (C-8a), 100.2 (C-3 ind), 111.4 (C-4 ind), 119.8 (C-5 ind), 120.6 (C-4 ind), 122.3 (C-6 ind), 126.3 (C-o); 127.5, 127.6 (C-p, C-2 ind), 128.6 (C-m), 136.0 (C-3a ind), 137.0 (C-3a ind), 141.5 (C-i), 166.8 (NCO), 171.2 (COO) ppm. IR (KBr): $\tilde{v} = 1641, 1739, 3267 \text{ cm}^{-1}$. HRMS: calcd. for $C_{27}H_{31}N_2O_4$ [M + H]+: 447.2278; found 447.2300.

Data for 20 (Lower R_f Epimer): Yellow foam. $[a]_D^{22} = +4.6$ (c = 1.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃, 25 °C): $\delta = 0.95$ (t, J =7.3 Hz, 3 H, CH₃ ethyl), 1.48–1.52 (m, 1 H, CH₂ ethyl), 1.83–1.95 (m, 3 H, CH₂ ethyl, 6-H, 8-H), 2.05 (s, 3 H, CH₃CO), 2.05-2.11 (m, 1 H, 7-H), 2.31–2.38 (m, 1 H, 6-H), 2.35 (d, J = 17.6, 5.6 Hz, 1 H, CH₂CHO), 2.59 (d, J = 17.6 Hz, 1 H, CH₂CHO), 3.40 (dd, J = 8.8, 1.2 Hz, 1 H, 2-H), 4.13 (dd, J = 9.2, 8.8 Hz, 1 H, 2-H), 4.65 (d, J = 9.2 Hz, 1 H, 8a-H), 4.92 (d, J = 6.8 Hz, 1 H, 3-H), 5.96 (dd, J = 9.2, 6.0 Hz, 1 H, CH₂CHO), 6.52 (d, J = 2.0 Hz, 1 H, 3-H ind), 7.11 (td, J = 7.6, 0.8 Hz, 1 H, ind-H), 7.17–7.32 (m, 7 H, ArH, ind-H), 7.59 (d, J = 8.4 Hz, 1 H, ind-H), 8.98 (br. s, 1 H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): δ = 11.4 (CH₃ ethyl), 20.9 (CH₂ ethyl), 21.2 (OCH₃), 30.2 (C-7), 31.8 (C-6), 37.5 (CH₂CHO), 44.2 (C-8), 59.4 (C-3), 69.2 (CH₂CHO), 73.9 (C-2), 90.1 (C-8a), 101.0 (C-3 ind), 111.4 (C-4 ind), 120.0 (C-5 ind), 120.8 (C-4 ind), 122.6 (C-6 ind), 126.3 (C-o), 127.5, 127.6 (C-p, C-2 ind), 128.6 (C-m), 135.8 (C-3a ind), 135.9 (C-3a ind), 141.4 (C-i), 166.7 (NCO), 171.0 (COO) ppm. IR (KBr): $\tilde{v} = 1645$, 1732, 3261 cm⁻¹. HRMS: calcd. for C₂₇H₃₀N₂NaO₄ [M + Na]⁺: 469.2098; found 469.2113.

(3R,75,8S,8aR)-8-Ethyl-7-[(2-indolyl)ethyl]-5-oxo-3-phenyl-2,3,6,7,8,8a-hexahydro-5*H*-oxazolo[3,2-*a*]pyridine (21): A solution of the acetates 20 (150 mg, 0.34 mmol) in EtOAc (20 mL) containing Pd(OH)₂ (20%, 30 mg) was hydrogenated at room temp. (400 psi pressure) for 2 d. The catalyst was removed by filtration, and the solvent was evaporated to give a foam. Flash chromatography (hexane/EtOAc 9:1 to 1:1) afforded 21 (71 mg, 54%).

Data for 21: Yellow foam. $[a]_{D}^{22} = -42.5$ (c = 0.2, CHCl₃). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 0.98 (t, J = 7.6 Hz, 3 H, CH₃ ethyl), 1.45-1.56 (m, 2 H, CH₂ ethyl, indCH₂CH₂), 1.82-1.93 (m, 2 H, CH₂ ethyl, indCH₂CH₂), 1.95-2.02 (m, 1 H, 8-H), 2.09-2.14 (m, 1 H, 7-H), 2.40 (dd, J = 18.0, 5.2 Hz, 1 H, indCH₂), 2.52 (dd, J = 18.0, 2.0 Hz, 1 H, indCH₂), 2.66 (ddd, J = 14.8, 10.0, 7.2 Hz, 1 H, 6-H), 2.95 (ddd, J = 14.8, 10.0, 4.8 Hz, 1 H, 6-H), 3.99 (dd, J = 9.2, 1.2 Hz, 1 H, 2-H), 4.11 (dd, J = 9.2, 7.2 Hz, 1 H, 2-H), 4.61 (d, J = 9.6 Hz, 1 H, 1 H, 8a-H), 4.89 (d, J = 6.0 Hz, 1 H, 3-H), 6.24 (d, J = 1.2 Hz, 1 H, 3-H ind), 7.05-7.53 (m, 9 H, ArH, ind-H), 8.07 (br. s, 1 H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): $\delta = 11.3$ (CH₃ ethyl), 20.9 (CH₂ ethyl), 26.5 (C-6), 27.5 (indCH₂CH₂), 32.4 (C-7), 36.8 (indCH₂), 44.1 (C-8), 59.3 (C-3), 73.8 (C-2), 90.3 (C-8a), 99.9 (C-3 ind), 110.4 (C-7 ind), 119.7 (C-5 ind), 119.8 (C-4 ind), 121.2 (C-6 ind), 126.3 (C-o), 127.5 (C-p), 128.6 (C-m), 128.7 (C-2 ind), 135.9 (C-3a ind), 138.3 (C-7a ind), 141.5 (C-*i*), 171.5 (NCO) ppm. IR (KBr): $\tilde{v} = 1642 \text{ cm}^{-1}$. HRMS: calcd. for C₂₅H₂₉N₂O₂ [M + H]⁺: 389.2224; found 389.2224.

(1*R*,5*S*,13*S*)-13-Ethyl-2-[(1*R*)-2-hydroxy-1-phenylethyl]-3-oxo-2,3,4,5,6,7-hexahydro-3*H*-1,5-methanoazocine[4,3-*b*]indole (22): TiCl₄ (1 mL of a 1.0 M solution in CH₂Cl₂, 1.0 mmol) was added at room temp. to a solution of 21 (38 mg, 0.10 mmol) in CH₂Cl₂ (2 mL), and the resulting mixture was heated at reflux for 24 h. TiCl₄ (1 mL of a 1.0 M solution in CH₂Cl₂, 1.0 mmol) was then once again added after a further 24 h, and the mixture was maintained at reflux for an additional 48 h. The mixture was poured into saturated aqueous NaHCO₃ and extracted with CH₂Cl₂. The combined organic extracts were dried and concentrated, and the resulting residue was chromatographed with a cartridge containing amine functionalized silica (hexane/EtOAc 1:1 to EtOAc/MeOH 1:1) to give 22 (22 mg, 58%).

Data for 22: Yellow foam. $[a]_{D}^{22} = -88.2$ (c = 0.5, CHCl₃). ¹H NMR (500 MHz, CDCl₃, 25 °C): δ = 0.72 (t, J = 7.5 Hz, 3 H, CH₃ ethyl), 1.11 (td, J = 7.5, 7.5, 2.0 Hz, 2 H, CH₂ ethyl), 1.73 (ddd, J = 14.0, 7.0, 5.0 Hz, 1 H, 6-H), 1.95 (dt, J = 14.0, 2.5 Hz, 1 H, 6-H), 2.05– 2.10 (m, 1 H, 13-H), 2.42–2.50 (m, 1 H, 5-H), 2.55 (ddd, J = 16.0, 5.0, 3.0 Hz, 1 H, 7-H), 2.75 (d, J = 18.5 Hz, 1 H, 4-H), 3.00 (dd, J = 18.5, 8.5 Hz, 1 H, 4-H), 3.12 (m, 1 H, 7-H), 3.54 (m, 1 H, $C_6H_5CHCH_2$), 3.80–3.83 (m, 1 H, $C_6H_5CHCH_2$), 4.51 (d, J = 5.0 Hz, 1 H, 1-H), 5.74 (m, 1 H, C₆H₅CHCH₂), 6.98–7.31 (m, 9 H, ArH, ind-H), 8.03 (br. s, 1 H, NH) ppm. ¹³C NMR (125.9 MHz, CDCl₃, 25 °C): δ = 11.7 (CH₃ ethyl), 23.0 (CH₂ ethyl), 23.4 (C-6), 26.9 (C-7), 33.8 (C-5), 38.4 (C-4), 41.7 (C-13), 53.0 (C-1), 60.5 (C₆H₅CHCH₂), 63.2 (C₆H₅CHCH₂), 110.6 (C-12b), 110.8 (C-9), 117.4 (C-12), 119.6 (C-11), 121.0 (C-10), 127.6 (C-m), 128.1 (C-o), 128.2 (C-7a), 128.3 (C-p), 133.9 (C-12a), 136.9 (C-8a), 138.5 (C-i), 172.1 (NCO) ppm. IR (KBr): $\tilde{v} = 1608$, 2926 cm⁻¹. HRMS: calcd. for C₂₅H₂₉N₂O₂ [M + H]⁺: 389.2224; found 389.2222.

Acknowledgments

Financial support from the Spanish Ministerio de Ciencia e Innovación (MICINN) (project number CTQ2009-07021/BQU), and the AGAUR, Generalitat de Catalunya (grant number 2009-



SGR-1111) is gratefully acknowledged. Thanks are also due to the MICINN for a fellowship to B. C.

- For reviews, see: a) D. Romo, A. I. Meyers, *Tetrahedron* 1991, 47, 9503–9569; b) A. I. Meyers, G. P. Brengel, *Chem. Commun.* 1997, 1–8; c) M. D. Groaning, A. I. Meyers, *Tetrahedron* 2000, 56, 9843–9873; d) C. Escolano, M. Amat, J. Bosch, *Chem. Eur. J.* 2006, *12*, 8198–8207.
- [2] M. Amat, M. Pérez, A. T. Minaglia, J. Bosch, J. Org. Chem. 2008, 73, 6920–6923.
- [3] a) M. Amat, M. Pérez, N. Llor, J. Bosch, E. Lago, E. Molins, Org. Lett. 2001, 3, 611–614; b) M. Amat, M. Pérez, N. Llor, J. Bosch, Org. Lett. 2002, 4, 2787–2790.
- [4] a) M. Amat, M. Pérez, A. T. Minaglia, N. Casamitjana, J. Bosch, *Org. Lett.* 2005, *7*, 3653–3656; b) M. Amat, M. Pérez, A. T. Minaglia, B. Peretto, J. Bosch, *Tetrahedron* 2007, *63*, 5839–5848; c) M. Amat, E. Brunaccini, B. Checa, M. Pérez, N. Llor, J. Bosch, *Org. Lett.* 2009, *11*, 4370–4373.
- [5] M. Amat, J. Bosch, J. Hidalgo, M. Cantó, M. Pérez, N. Llor, E. Molins, C. Miravitlles, M. Orozco, J. Luque, J. Org. Chem. 2000, 65, 3074–3084.
- [6] M. Amat, N. Llor, B. Checa, E. Molins, J. Bosch, J. Org. Chem. 2010, 75, 178–189.
- [7] M. Amat, M. Pérez, S. Proto, T. Gatti, J. Bosch, Chem. Eur. J. 2010, 16, 9438–9441.
- [8] M. Amat, M. Pérez, N. Llor, C. Escolano, F. J. Luque, E. Molins, J. Bosch, J. Org. Chem. 2004, 69, 8681–8693.
- [9] M. Amat, N. Llor, B. Checa, M. Pérez, J. Bosch, *Tetrahedron Lett.* 2007, 48, 6722–6725.
- [10] For conjugate addition reactions to polycyclic unsaturated lactams, see: a) E. García, E. Lete, N. Sotomayor, J. Org. Chem. 2006, 71, 6776–6784; b) S. M. Allin, J. S. Khera, J. Witherington, M. R. J. Elsegood, Tetrahedron Lett. 2006, 47, 5737–5739; c) S. M. Allin, J. S. Khera, C. I. Thomas, J. Witherington, K. Doyle, M. R. J. Elsegood, M. Edgar, Tetrahedron Lett. 2006, 47, 1961–1964; d) C. Camarero, I. González-Temprano, E. Lete, N. Sotomayor, Synlett 2007, 1101–1105; e) C. Camarero, I. González-Temprano, A. Gómez-SanJuan, S. Arrasate, E. Lete, N. Sotomayor, Tetrahedron 2009, 65, 5787–5798.
- [11] M. Amat, N. Llor, J. Hidalgo, J. Bosch, *Tetrahedron: Asym*metry **1997**, 8, 2237–2240.
- [12] a) T. Fujii, M. Ohba, J. Sakaguchi, *Chem. Pharm. Bull.* 1987, 35, 3628–3640; b) A. Deiters, M. Pettersson, S. F. Martin, *J. Org. Chem.* 2006, 71, 6547–6561; see also ref.^[3b,8,9]
- [13] For the relative configuration at the epimerizable C-6 stereocenter, see the Exp. Section. The relative configuration at C-6 was deduced from the 6-H/7-H coupling constant of 6-H in the NMR spectra.
- [14] a) P. Deslongchamps, Stereoelectronic Effects in Organic Chemistry; Pergamon Press, Oxford, 1983, p. 221; b) P. Perlmutter, Conjugate Addition Reactions in Organic Synthesis, Pergamon Press, Oxford, 1992, p. 25.
- [15] See ref.^[2,3a,4b,4c,5-7] For a discussion of the stereochemical outcome (kinetic vs. thermodynamic control) in conjugate addition reactions to unsaturated δ-lactams, see ref.^[3b,8,9]
- [16] Data for 13: Yellow foam. $[a]_{D}^{22} = -14.4 \ (c = 0.35, \text{ CHCl}_3)$. ¹H NMR (400 MHz, CDCl₃, 25 °C): $\delta = 0.95 \ (t, J = 7.6 \text{ Hz}, 3 \text{ H}, 3 \text{ H})$

CH₃ ethyl), 1.94–1.99 (m, 2 H, CH₂ ethyl), 2.62 (dd, J = 16.0, 2.2 Hz, 1 H, CH₂CO), 2.76 (dd, J = 16.0, 6.0 Hz, 1 H, CH₂CO), 2.76–2.82 (m, 2 H, 3-H), 2.89–2.95 (m, 1 H, 4-H), 4.11–4.17 (m, 2 H, 2'-H), 5.85 (t, J = 7.2 Hz, 1 H, 1'-H), 5.94 (s, 1 H, 6-H), 6.75 (d, J = 1.6 Hz, 1 H, 3-H ind), 7.25–7.42 (m, 8 H, ArH, H ind), 7.58 (d, J = 8.4 Hz, 1 H, 4-H ind), 9.53 (br. s, 1 H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): $\delta = 12.6$ (CH₃ ethyl), 25.5 (CH₂ ethyl), 31.2 (C-4), 37.3 (CH₂CO), 39.5 (C-3), 57.9 (C-1'), 62.1 (C-2'), 110.0 (C-3 ind), 112.2 (C-7 ind), 120.5 (C-6), 120.8 (C-4 ind), 123.0 (C-5 ind), 125.9 (C-5), 126.4 (C-6 ind), 127.3 (C-3a ind), 127.6 (C-0), 127.9 (C-p), 128.8 (C-m), 135.2 (C-i), 137.6 (C-2 ind), 137.7 (C-7a ind), 169.5 (NCO), 191.2 (CO) ppm. IR (KBr): $\tilde{v} = 1635$ cm⁻¹. HRMS: calcd. for C₂₅H₂₇N₂O₃ [M + H]⁺: 403.2016; found 403.2016.

- [17] For the isomerization of 3,8a-cis-oxazolopiperidone lactams to the more stable 3,8a-trans isomers, see: a) M. Amat, C. Escolano, A. Gómez-Esqué, O. Lozano, N. Llor, R. Griera, E. Molins, J. Bosch, Tetrahedron: Asymmetry 2006, 17, 1581–1588; b) M. Amat, M. M. M. Santos, O. Bassas, N. Llor, C. Escolano, A. Gómez-Esqué, E. Molins, S. M. Allin, V. McKee, J. Bosch, J. Org. Chem. 2007, 72, 5193–5201; c) M. Amat, M. Pérez, A. T. Minaglia, D. Passarella, J. Bosch, Tetrahedron: Asymmetry 2008, 19, 2406–2410; see also ref.^[5]
- [18] For recent reviews on the chemistry of *N*-acyliminium ions, see:
 a) W. N. Speckamp, M. J. Moolenaar, *Tetrahedron* 2000, 56, 3817–3856;
 b) B. E. Maryanoff, H.-C. Zhang, J. H. Cohen, I. J. Turchi, C. A. Maryanoff, *Chem. Rev.* 2004, 104, 1431–1628.
- [19] For the total synthesis of ervitsine in the racemic series, see: a) M.-Ll. Bennasar, B. Vidal, J. Bosch, J. Org. Chem. 1997, 62, 3597–3609; for the enantioselective synthesis of N-methylervitsine, see: b) M.-Ll. Bennasar, E. Zulaica, Y. Alonso, J. Bosch, Tetrahedron: Asymmetry 2003, 14, 469–479; c) M.-Ll. Bennasar, B. Vidal, J. Bosch, Chem. Commun. 1996, 2756–2757.
- [20] Data for the **8a** epimer of *cis*-**6**: Yellow foam. $[a]_{E}^{2} = -38.0$ (c = 0.2, CHCl₃). ¹H NMR (400 MHz, CDCl₃, 25 °C): $\delta = 1.06$ (t, J = 7.2 Hz, 3 H, CH₃ ethyl), 1.16–1.83 (m, 8 H, CH₂ ethyl, 6-H, 7-H, 8-H, CH₂CO), 3.77 (t, J = 8.4 Hz, 1 H, 2-H), 4.50 (t, J = 8.4 Hz, 1 H, 2-H), 4.89 (m, 1 H, 8a-H), 5.22 (m, 1 H, 3-H), 7.15–7.43 (m, 9 H, ArH, ind-H), 7.73 (d, J = 8.0 Hz, 1 H, ind-H), 9.09 (br. s, 1 H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): $\delta = 10.0$ (CH₃ ethyl), 21.3 (CH₂ ethyl), 29.7 (C-7), 30.4 (*C*H₂CO), 40.3 (C-6), 41.5 (C-8), 58.3 (C-3), 72.7 (C-2), 91.2 (C-8a), 112.2 (C-H ind), 135.0 (C-*i*), 137.4 (C-3a ind), 139.7 (C-7a ind), 167.9 (NCO), 190.8 (CO) ppm. IR (KBr): $\tilde{v} = 1652$ cm⁻¹. HRMS: calcd. for C₂₅H₂₇N₂O₃ [M + H]⁺: 403.2016; found 403.2014.
- [21] M. Andriantsiferana, R. Besselièvre, C. Riche, H.-P. Husson, *Tetrahedron Lett.* 1977, 18, 2587–2590.
- [22] For the chemoselective oxidation of a 2-indolylmethyl to a 2-acylindole moiety, see: a) Y. Ban, K. Yoshida, J. Goto, T. Oishi, J. Am. Chem. Soc. 1981, 103, 6990–6992; b) Y. Ban, K. Yoshida, J. Goto, T. Oishi, E. Takeda, *Tetrahedron* 1983, 39, 3657–3668; c) T. Fujii, M. Ohba, J. Sakaguchi, Chem. Pharm. Bull. 1987, 35, 3628–3640; d) J. Gracia, N. Casamitjana, J. Bonjoch, J. Bosch, J. Org. Chem. 1994, 59, 3939–3951.

Received: July 19, 2010 Published Online: December 14, 2010